Ruxolitinib – Uses, Dosage, Side Effects, Interaction

Ruxolitinib is an antineoplastic agent that inhibits cell proliferation, induces apoptosis of malignant cells, and reduces pro-inflammatory cytokine plasma levels by inhibiting JAK-induced phosphorylation of signal transducer and activator of transcription (STAT). Inhibition of STAT3 phosphorylation, which is used as a marker of JAK activity, by ruxolitinib is achieved at two hours after dosing which returned to near baseline by 10 hours in patients with myelofibrosis and polycythemia vera. In clinical trials, ruxolitinib reduced splenomegaly and improved symptoms of myelofibrosis. In a mouse model of myeloproliferative neoplasms, administration of ruxolitinib was associated with prolonged survival. Ruxolitinib inhibits both mutant and wild-type JAK2; however, JAK2V617F mutation, which is often seen in approximately 50% of patients with myelofibrosis, was shown to reduce ruxolitinib sensitivity, which may also be associated with possible resistance to JAK inhibitor treatment.

Indications

• Ruxolitinib is indicated for the treatment of the following conditions: – intermediate or high-risk myelofibrosis (MF), including prima1y MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults. It is also used to treat disease-related splenomegaly or symptoms in adult patients with these conditions. – polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea. – steroid-refracto1y acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older. – chronic GVHD in patients aged 12 years and older who have failed one or two lines of systemic therapy. Topical ruxolitinib is indicated for: – the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. – the treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
• Myelofibrosis (MF): Jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.
• Polycythaemia vera (PV): Jakavi is indicated for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.
• Graft versus host disease (GvHD): Jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have an inadequate response to corticosteroids or other systemic therapies.
• Ruxolitinib is a small molecule Janus kinase inhibitor that is used in the treatment of intermediate or high-risk myelofibrosis and resistant forms of polycythemia vera and graft-vs-host disease.
• Treatment of vitiligo.
• Ruxolitinib is a kinase inhibitor used to treat various types of myelofibrosis, and polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment.
• Acute Graft-Versus-Host Disease (GVHD)
• Chronic Graft Versus Host Disease
• Non-segmental Vitiligo
• Post Polycythemia Vera Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
• Primary Myelofibrosis (PMF)
• High-risk Myelofibrosis
• Intermediate risk Myelofibrosis
• Mild Atopic dermatitis
• Moderate Atopic dermatitis
• Refractory Polycythemia vera

Use in Cancer

Ruxolitinib phosphate is approved for use in adults to treat:

• Myelofibrosis (a bone marrow disease) that is an intermediate risk or high risk, including the following types:
  • Primary myelofibrosis.
  • Post-polycythemia vera myelofibrosis.
  • Post-essential thrombocythemia myelofibrosis.
• Polycythemia vera in patients who cannot be treated with or have not gotten better with hydroxyurea.

Ruxolitinib phosphate is also being studied in the treatment of some types of cancer.

Contraindications

• active tuberculosis
• a bad infection
• cancer or malignancy
• squamous cell carcinoma
• anemia
• decreased blood platelets
• low levels of a type of white blood cell called neutrophils
• hardening of the arteries due to plaque buildup
• obstruction of a blood vessel by a blood clot
• a blood clot
• a patient who is producing milk and breastfeeding
• basal cell carcinoma of the skin
• malignant lymphoma
• progressive multifocal leukoencephalopathy, a type of brain infection
• a type of skin cancer called Merkel cell carcinoma
• chronic kidney disease stage 3A (moderate)
• chronic kidney disease stage 3B (moderate)
• chronic kidney disease stage 4 (severe)
• chronic kidney disease stage 5 (failure)
• kidney disease with likely reduction in kidney function
• Child-Pugh class A liver impairment
• Child-Pugh class B liver impairment
• Child-Pugh class C liver impairment

Dosage

Strengths: 5 mg; 10 mg; 15 mg; 20 mg; 25 mg

Myeloproliferative Disorder

• Doses should be titrated based on safety and efficacy; CBC (complete blood count) and platelet counts should be performed every 2 to 4 weeks until doses are stabilized and then as clinically indicated

Initial Dose Based on Platelet Count:

• Platelets greater than 200 x 10(9)/L: 20 mg orally twice a day
• Platelets 100 x 10(9)/L to 200 x 10(9)/L: 15 mg orally twice a day
• Platelets 50 x 10(9)/L to less than 100 x 10(9)/L: 5 mg orally twice a day

INSUFFICIENT RESPONSE: Failure to achieve a reduction from baseline in either palpable spleen length of 50% or a 35% reduction in spleen volume as measured by computed tomography (CT) or magnetic resonance imaging (MRI); Platelet count greater than 125 × 10(9)/L at 4 weeks and platelet count never below 100 × 10(9)/L; ANC Levels greater than 0.75 × 10(9)/L

For Patients Starting Treatment with a Platelet Count of 100 × 10(9)/L or greater:

• May increase in 5 mg twice a day increments after the first 4 weeks and then no more frequently than every 2 weeks if the response is insufficient and platelet and neutrophil counts are adequate; MAXIMUM DOSE: 25 mg orally twice a day

For Patients Starting Treatment with a Platelet Count of 50 to less than 100 × 10(9)/L or greater:

• May increase in 5 mg once a day increments to a maximum of 5 mg twice a day after the first 4 weeks and then no more frequently than every 2 weeks if the response is insufficient and platelet count remains at least 40 × 10(9)/L, platelet count has not fallen by more than 20% in the prior 4 weeks, the ANC is more than 1 × 10(9)/L, and the dose has not been reduced or interrupted for an adverse event or hematological toxicity in the prior 4 weeks.

DOSE MODIFICATIONS FOR HEMATOLOGIC TOXICITY: For Patients Starting Treatment with a Platelet Count of 100 × 10(9)/L or greater:
INTERRUPT treatment for PLATELET COUNTS less than 50 x 10(9)/L or ANC (absolute neutrophil count) less than 0.5 x 10(9)/L: RESTART once platelet count is above 50 x 10(9)/L and ANC above 0.75 x 10(9)/L

• When restarting, begin with a dose that is at least 5 mg twice a day below the dose at the interruption
• Maximum Restarting Dose after Interruption for Thrombocytopenia:
• Platelet Count: Greater than or equal to 125 × 10(9)/L: Restart at no more than 20 mg twice a day
• Platelet Count 100 to less than 125 × 10(9)/L: Restart at no more than 15 mg twice a day
• Platelet Count 75 to less than 100 × 10(9)/L: Restart at no more than 10 mg twice a day for at least 2 weeks; if stable, may increase to 15 mg twice a day
• Platelet Count 50 to less than 75 × 10(9)/L: Restart at no more than 5 mg twice a day for at least 2 weeks; if stable, may increase to 10 mg twice a day

INTERRUPT treatment for ANC below 0.5 × 10(9)/L, restart once ANC recovers to 0.75 × 10(9)/L or greater: Restart at the higher of 5 mg once a day OR 5 mg twice a day below the largest dose in the week prior to the treatment interruption

DOSE REDUCTIONS: To Avoid Dose Interruptions for Thrombocytopenia Among Patients Starting Treatment with a Platelet Count of 100 x 10(9)/L or greater, consider the following:
If the Dose at the time of Thrombocytopenia is 25 mg twice a day:

• Reduce the dose to 20 mg twice a day for a platelet count of 100 to less than 125 x 10(9)/L
• Reduce the dose to 10 mg twice a day for a platelet count of 75 to less than 100 x 10(9)/L
• Reduce the dose to 5 mg twice a day for a platelet count of 50 to less than 75 x 10(9)/L

If the Dose at the time of Thrombocytopenia is 20 mg twice a day:

• Reduce the dose to 15 mg twice a day for a platelet count of 100 to less than 125 x 10(9)/L
• Reduce the dose to 10 mg twice a day for a platelet count of 75 to less than 100 x 10(9)/L
• Reduce the dose to 5 mg twice a day for a platelet count of 50 to less than 75 x 10(9)/L

If the Dose at the time of Thrombocytopenia is 15 mg twice a day:

• Reduce the dose to 10 mg twice a day if the platelet count is 75 to less than 100 x 10(9)/L
• Reduce the dose to 5 mg twice a day if the platelet count is 50 to less than 75 x 10(9)/L

If the Dose at the time of Thrombocytopenia is 10 mg twice a day:

• Reduce the dose to 5 mg twice a day if the platelet count is 50 to less than 75 x 10(9)/L

DOSE MODIFICATIONS FOR HEMATOLOGIC TOXICITY: For Patients Starting Treatment with a Platelet Count of 50 to less than 100 × 10(9)/L or greater:

INTERRUPT treatment for PLATELET COUNTS less than 25 x 10(9)/L or ANC less than 0.5 x 10(9)/L
RESTART once platelet count is above 35 x 10(9)/L and ANC above 0.75 x 10(9)/L

• Restart at the higher of 5 mg once a day or 5 mg twice a day below the largest dose in the week prior to the decrease in platelet count below 25 x 10(9)/L or ANC below 0.5 x 10(9)/L that led to dose interruption

REDUCE dose for PLATELET COUNTS less than 35 x 10(9)/L:

• Platelet Count less than 25 x 10(9)/L: Interrupt dosing
• Platelet Count 25 to less than 35 x 10(9)/L AND the platelet count decline is less than 20% during the prior 4 weeks: Decrease by 5 mg once a day; for patients on 5 mg once a day, maintain this dose
• Platelet Count 25 to less than 35 x 10(9)/L AND the platelet count decline is 20% or greater during prior 4 weeks: Decrease by 5 mg twice a day; for patients on 5 mg twice a day, decrease to 5 mg once a day; for patients on 5 mg once a day, maintain this dose

DOSE MODIFICATION FOR BLEEDING:

• Interrupt treatment for bleeding requiring intervention regardless of current platelet count
• Once bleeding event resolves, consider resuming at prior dose if the underlying cause of bleeding has been controlled
• If the bleeding event has resolved but the underlying cause persists, consider resuming treatment with at a lower dose
• Based on limited clinical data, long-term maintenance at 5 mg twice a day has not shown benefit; this dose should be limited to patients for whom the benefits outweigh the potential risks.
• Discontinue therapy if there is no spleen size reduction or symptom improvement after 6 months of therapy.
• For the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF.

Graft Versus Host Disease

• Monitor complete blood counts (CBC), including platelet count and ANC, and bilirubin prior to
  initiating therapy, every 2 to 4 weeks until doses are stabilized, and then as indicated clinically: Acute Graft-Versus-Host Disease (GVHD): Initial dose: 5 mg orally 2 times a day
• Dose titration: Consider increasing the dose to 10 mg orally 2 times a day after at least 3 days if the ANC (absolute neutrophil count) and platelet counts are not decreased by 50% or more relative to the first day of dosing
• Duration of therapy: Consider tapering after 6 months for those with response who have stopped therapeutic doses of corticosteroids; taper by 1 dose level every 8 weeks (see comments); if signs or symptoms of GVHD recur during or after the taper, consider retreatment
• Chronic GVHD: Initial dose: 10 mg orally 2 times a day
• Duration of therapy: Consider tapering after 6 months for those with response who have stopped therapeutic doses of corticosteroids; taper by 1 dose level every 8 weeks (see comments); if signs or symptoms of GVHD recur during or after the taper, consider retreatment
• The dose level decreases from 10 mg twice a day to 5 mg once a day.
• See the Dose Adjustment section for dose modification guidance for adverse reactions.
• For the treatment of steroid-refractory acute GVHD and treatment of chronic GVHD after the failure of 1 or 2 lines of systemic therapy.

Polycythemia Vera

• Doses should be titrated based on safety and efficacy; CBC and platelet counts should be performed every 2 to 4 weeks until doses are stabilized and then as clinically indicated
• Initial dose: 10 mg orally twice a day
• The dose may be titrated based on safety and efficacy

INSUFFICIENT RESPONSE: Consider dose increases in patients with inadequate efficacy as demonstrated by one or more of the following: Continued need for phlebotomy; WBC greater than the upper limit of normal range; Platelet count greater than the upper limit of normal range; Palpable spleen that is reduced by less than 25% from baseline; Platelet count greater than or equal to 140 × 10(9)/L;. Hb (hemoglobin) greater than or equal to 12 g/dL; ANC greater than or equal to 1.5 × 10(9)/L
DOSE INCREASES: Increased dose in 5 mg twice a day increments to a MAXIMUM of 25 mg twice a day; doses should not be increased during the first 4 weeks of therapy and not more frequently than every two weeks

DOSE REDUCTIONS: Dose reductions should be considered for Hb and platelet count decreases:

• Hb greater than or equal to 12 g/dL AND platelet count greater than or equal to 100 × 10(9)/L: No change needed
• Hb 10 to less than 12 g/dL AND platelet count 75 to less than 100 × 10(9)/L: Dose reductions should be considered with the goal of avoiding dose interruptions for anemia and thrombocytopenia
• Hb 8 to less than 10 g/dL OR platelet count 50 to less than 75 × 10(9)/L: Reduce dose by 5 mg twice a day; for patients on 5 mg twice a day, decrease the dose to 5 mg once a day
• Hb less than 8 g/dL OR platelet count less than 50 × 10(9)/L OR ANC less than 1 x 10(9)/L: Interrupt dosing.

RESTARTING THERAPY:  After recovery of the hematologic parameter(s) to acceptable levels, dosing may be restarted. Restarted doses may be titrated, but the maximum total daily dose should not exceed 5 mg less than the dose that resulted in the dose interruption (One exception: following phlebotomy-associated anemia, the maximal total daily dose allowed would not be limited). Use the most severe category of a patient’s Hb, platelet count, or ANC abnormality to determine the corresponding MAXIMUM restarting dose:

• Hb 8 to less than 10 g/dL OR platelet count 50 to less than 75 × 10(9)/L OR ANC 1 to less than 1.5 × 10(9)/L: MAXIMUM restarting dose: 5 mg twice a day or no more than 5 mg twice a day less than the dose which resulted in dose interruption
• Hb 10 to less than 12 g/dL OR platelet count 75 to less than 100 × 10(9)/L OR ANC 1.5 to less than 2 × 10(9)/L: MAXIMUM restarting dose: 10 mg twice day or no more than 5 mg twice a day less than the dose which resulted in dose interruption
• Hb greater than or equal to 12 g/dL OR platelet count greater than or equal to 100 × 10(9)/L OR ANC greater than or equal to 2 × 10(9)/L: MAXIMUM restarting dose: 15 mg twice a day or no more than 5 mg twice a day less than the dose which resulted in dose interruption
• Dose should be continued for at least 2 weeks, if stable may increase dose by 5 mg twice a day
• For treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.

Graft Versus Host Disease

12 years or older:

Monitor complete blood counts (CBC), including platelet count and ANC, and bilirubin prior to
initiating therapy, every 2 to 4 weeks until doses are stabilized, and then as indicated clinically:

• Acute Graft-Versus-Host Disease (GVHD): Initial dose: 5 mg orally 2 times a day
• Dose titration: Consider increasing the dose to 10 mg orally 2 times a day after at least 3 days if the ANC (absolute neutrophil count) and platelet counts are not decreased by 50% or more relative to the first day of dosing
• Duration of therapy: Consider tapering after 6 months for those with response who have stopped therapeutic doses of corticosteroids; taper by 1 dose level every 8 weeks (see comments); if signs or symptoms of GVHD recur during or after the taper, consider retreatment
• Chronic GVHD: Initial dose: 10 mg orally 2 times a day
• Duration of therapy: Consider tapering after 6 months for those with response who have stopped therapeutic doses of corticosteroids; taper by 1 dose level every 8 weeks (see comments); if signs or symptoms of GVHD recur during or after the taper, consider retreatment
• The dose level decreases from 10 mg twice a day to 5 mg once a day.
• See the Dose Adjustment section for dose modification guidance for adverse reactions.
• For the treatment of steroid-refractory acute GVHD and treatment of chronic GVHD after the failure of 1 or 2 lines of systemic therapy in pediatric patients 12 years or older.

Renal Dose Adjustments

• Mild Renal Impairment (CrCl 60 mL/min or greater): No adjustment recommended

Moderate or Severe Renal Impairment (CrCl 15 to less than 60 mL/min):

• MF: Platelet Count greater than 150 x 10(9)/L: No adjustment recommended
• MF: Platelet Count: 100 to 150 x 10(9)/L: Initial dose: 10 mg twice a day
• MF: Platelet Count: 50 to less than 100 x 10(9)/L: Initial dose: 5 mg once a day
• MF: Platelets less than 50 x 10(9)/L: Avoid use
• MF: ESRD (CrCl less than 15 mL/min) not on dialysis: Avoid use
• MF: ESRD on dialysis: See Dialysis

Moderate or Severe Renal Impairment (CrCl 15 to less than 60 mL/min):

• PV: Initial dose: 5 mg twice a day
• PV: ESRD (CrCl less than 15 mL/min) not on dialysis: Avoid use
• PV: ESRD on dialysis: See Dialysis

Moderate or Severe Renal Impairment (CrCl 15 to less than 60 mL/min):

• Acute GVHD: Initial dose: 5 mg once a day
• Chronic GVHD: Initial dose: 5 mg twice a day
• GVHD (acute or chronic) (CrCl less than 15 mL/min) not on dialysis: Avoid the use
• GVHD (acute or chronic): ESRD on dialysis: See Dialysis

Liver Dose Adjustments

Mild, Moderate, or Severe Hepatic Impairment (Child-Pugh Class A, B, C):

• MF: Platelet Count greater than 150 x 10(9)/L: No adjustment recommended
• MF: Platelet Count: 100 to 150 x 10(9)/L: Initial dose: 10 mg twice a day
• MF: Platelet Count: 50 to less than 100 x 10(9)/L: Initial dose: 5 mg once a day
• MF: Platelets less than 50 x 10(9)/L: Avoid use

Mild, Moderate, or Severe Hepatic Impairment (Child-Pugh Class A, B, C):

• PV: Initial dose: 5 mg twice a day

Acute GVHD:

• Mild, Moderate, or Severe Hepatic Impairment (based on NCI criteria without liver GVHD): No adjustment is recommended
• Stage 1, 2, or 3 Liver Acute GVHD: No adjustment recommended
• Stage 4 Liver Acute GVHD: Initial dose: 5 mg once a day

Chronic GVHD:

• Mild, Moderate or Severe Hepatic Impairment (based on NCI criteria without liver GVHD): No adjustment is recommended
• Score 1 or 2 Liver Chronic GVHD: No adjustment recommended
• Score 3 Liver Chronic GVHD: Monitor blood counts more frequently for toxicity and modify dosage for adverse reactions if they occur

Dose Adjustments

DRUG INTERACTIONS:

• Avoid concomitant use of Ruxolitinib with Fluconazole at doses greater than 200 mg/day
• Modify the dose of Ruxolitinib when used with Strong CYP450 3A4 Inhibitors or Fluconazole less than 200 mg/day
• MF: Initial dose with platelets 100 x 10(9)/L or greater: 10 mg twice a day
• MF: Initial dose with platelets 50 to less than 100 x 10(9)/L: 5 mg once a day
• PV: Initial dose: 5 mg twice a day

MF OR PV ON STABLE RUXOLITINIB (adding strong CYP450 3A4 inhibitor or fluconazole dose less than 200 mg/day):

• A dose greater than or equal to 10 mg twice a day: Decrease dose by 50% (rounded to closest tablet strength)
• Stable on 5 mg twice a day: Reduce to 5 mg once a day
• Stable on 5 mg once a day: Avoid the use of strong CYP450 3A4 inhibitor or fluconazole or interrupt ruxolitinib for the duration of strong CYP450 3A4 inhibitor or fluconazole use

ACUTE GVHD: With fluconazole 200 mg/day or less: Initial dose: 5 mg once a day
CHRONIC GVHD: With fluconazole 200 mg/day or less: Initial dose: 5 mg twice a day
ACUTE OR CHRONIC GVHD: With CYP450 3A4 Inhibitors: Monitor blood counts more frequently for toxicity and modify the ruxolitinib dosage for adverse reactions if they occur
GVHD: DOSE MODIFICATIONS for ADVERSE REACTIONS

Dose Level Reductions for Patients with GVHD:

• A dose of 10 mg twice a day should be reduced to 5 mg twice a day
• A dose of 5 mg twice a day should be reduced to 5 mg once a day
• Patients unable to tolerate 5 mg once a day should have treatment interrupted until their clinical and/or laboratory parameters recover

DOSE MODIFICATION for Patients with ACUTE GVHD:

• Clinically significant thrombocytopenia after supportive measures: Reduce dose by 1 level; when platelets recover to previous values, dosing may return to prior dose level
• ANC less than 1 × 10(9) considered related to therapy: Hold for up to 14 days; resume at 1 dose level lower upon recovery
• Total Bilirubin Elevation, no liver GVHD:
• Total bilirubin elevated 3 to 5 × ULN (times upper limit of normal), continue at 1 dose level lower until recovery
• Total bilirubin elevated greater than 5 to less than 10 × ULN, hold for up to 14 days until bilirubin is 1.5 or less than ULN, resume at current dose upon recovery
• Total bilirubin greater than 10 × ULN, hold for up to 14 days until bilirubin is 1.5 or less than ULN, resume at 1 dose level lower upon recovery
• Total Bilirubin Elevation, liver GVHD: Total bilirubin greater than 3 × ULN, continue at 1 dose level lower until recovery

DOSE MODIFICATION for Patients with CHRONIC GVHD:

• Platelet count less than 20 × 10(9)/L: Reduce by 1 dose level; if resolved within 7 days, may return to initial dose level, if not resolved within 7 days, maintain at 1 dose level lower
• ANC less than 0.75 × 10(9)/L (considered related to therapy): Reduce by 1 dose level, resume at initial dose level upon recovery
• ANC less than 0.5 × 10(9)/L (considered related to therapy): Hold for up to 14 days, resume at 1 dose level lower upon recovery; may resume initial dose level when ANC greater than 1 × 10(9)/L
• Total bilirubin elevated 3 to 5 × ULN: Continue at 1 dose level lower until recovery; if resolved within 14 days, then increase by 1 dose level, if not resolved within 14 days, then maintain the decreased dose level
• Total bilirubin elevated greater than 5 to less than 10 × ULN: Hold for up to 14 days until resolved; resume at current dose upon recovery, if not resolved within 14 days, resume at 1 dose level lower upon recovery
• Total bilirubin greater than 10 × ULN: Hold for up to 14 days until resolved, resume at 1 dose level lower upon recovery, if not resolved within 14 days, discontinue
• Other Adverse Reactions: Grade 3: Continue at 1 dose level lower until recovery
• Other Adverse Reactions: Grade 4: Discontinue

Therapy Discontinuation:

• MF or PV: When discontinuing therapy for reasons other than thrombocytopenia, a gradual tapering should be considered, for example by 5 mg twice daily each week.
• Acute or Chronic GVHD: Consider tapering therapy after 6 months in patients with response who have discontinued therapeutic doses of corticosteroids; taper by 1 dose level approximately every 8 weeks (10 mg twice daily to 5 mg once daily). If GVHD signs or symptoms recur during or after the taper, consider retreatment

Administration advice:

• Take orally without regard to meals
• For a missed dose, the patient should not take an additional dose but should take the next usual scheduled dose
• Suspend 1 table in approximately 40 mL of water; stir for approximately 10 minutes
• Administer suspension using an appropriate syringe within 6 hours of the tablet being dispersed; rinse with 75 mL of water after administration
• The effect of tube-feeding preparations on drug exposure has not been evaluated
• Perform pretreatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated
• Perform periodic skin examinations
• Assess lipid parameters approximately 8¬ to 12 weeks following initiation of therapy; monitor accordingly
• Patients should be advised to read the FDA-approved patient labeling (Patient Information).
• Patients should be aware of potential adverse events including thrombocytopenia, anemia, neutropenia, infections, and increased cholesterol.
• Patients should be advised to continue therapy as prescribed and talk with their healthcare provider prior to discontinuation.
• Patients should be aware that drug interactions may require dose modifications and they should discuss all medication use with their healthcare provider.

Side Effects

The Most Common

• dizziness
• headache
• tiredness
• shortness of breath
• weight gain
• gas
• diarrhea
• constipation
• nausea
• rash
• muscle or joint pain
• swelling of the arms, legs or other parts of the body
• unusual or heavy bleeding or bruising
• fever, sore throat, chills, cough, chest pain, night sweats, frequent, painful, urgent urination, and other signs of infection
• burning, tingling, itching, or skin sensitivity on one side of the body or face with painful rash or blisters appearing several days later.
• new sores, bumps, or discoloration or other changes to the skin
• pale skin, tiredness, or shortness of breath (especially while exercising)
• difficulty moving or keeping your balance, weakness of the legs or arms that keeps getting worse, difficulty understanding or speaking, loss of memory, vision problems, or changes in personality
• swelling, pain, tenderness, warmth or redness in one or both legs
• shortness of breath
• difficulty breathing
• pain in the chest, arms, back, neck, jaw, or stomach
• breaking out in cold sweat
• nausea or vomiting
• lightheadedness
• slow or difficult speech
• numbness or weakness of the face, arm, or leg on one side of your body

More common

• Black, tarry stools
• bladder pain
• bleeding gums
• blood in the urine or stools
• blurred vision
• bruising
• chest tightness
• chills
• cloudy urine
• collection of blood under the skin
• cough
• coughing up blood
• deep, dark purple bruise
• difficult, burning, or painful urination
• difficulty in breathing or swallowing
• dizziness
• fever
• frequent urge to urinate
• headache
• hoarseness
• increased menstrual flow or vaginal bleeding
• itching, pain, redness, or swelling
• large, flat, blue or purplish patches in the skin
• lower back or side pain
• nervousness
• nosebleeds
• painful or difficult urination
• pale skin
• paralysis
• pinpoint red spots on the skin
• pounding in the ears
• prolonged bleeding from cuts
• pus in the urine
• red or dark brown urine
• small, red or purple spots on the skin
• slow or fast heartbeat
• sore throat
• swelling
• tenderness, pain, swelling, warmth, skin discoloration, and prominent superficial veins over the affected area
• trouble breathing
• ulcers, sores, or white spots in the mouth
• unusual bleeding or bruising
• unusual tiredness or weakness

Rare

• Painful blisters on the trunk of the body
• Anxiety
• chest pain
• fainting
• pain, redness, or swelling in the arm or leg
• pains in the chest, groin, or legs, especially calves of the legs
• persistent non-healing sore
• pink growth
• reddish patch or irritated area
• severe headaches of sudden onset
• sudden loss of coordination
• sudden onset of slurred speech
• sudden vision changes
• shiny bump
• a white, yellow, or waxy scar-like area

Drug Interaction

DRUG	INTERACTION
Abacavir	Abacavir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Abaloparatide	The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Ruxolitinib.
Abametapir	The serum concentration of Ruxolitinib can be increased when it is combined with Abametapir.
Abatacept	The metabolism of Ruxolitinib can be increased when combined with Abatacept.
Abciximab	The risk or severity of bleeding can be increased when Abciximab is combined with Ruxolitinib.
Abrocitinib	The metabolism of Abrocitinib can be decreased when combined with Ruxolitinib.
Acalabrutinib	The metabolism of Ruxolitinib can be decreased when combined with Acalabrutinib.
Acebutolol	Ruxolitinib may increase the bradycardic activities of Acebutolol.
Aceclofenac	Aceclofenac may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Acemetacin	Acemetacin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Acenocoumarol	The risk or severity of bleeding can be increased when Acenocoumarol is combined with Ruxolitinib.
Acetaminophen	The metabolism of Ruxolitinib can be increased when combined with Acetaminophen.
Acetazolamide	The metabolism of Ruxolitinib can be decreased when combined with Acetazolamide.
Acetohexamide	The metabolism of Ruxolitinib can be decreased when combined with Acetohexamide.
Acetyl sulfisoxazole	The metabolism of Ruxolitinib can be decreased when combined with Acetyl sulfisoxazole.
Acetylsalicylic acid	The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Ruxolitinib.
Aclidinium	Ruxolitinib may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine	Ruxolitinib may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Acyclovir	Acyclovir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Adalimumab	The metabolism of Ruxolitinib can be increased when combined with Adalimumab.
Adefovir dipivoxil	Adefovir dipivoxil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Adenovirus type	The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Ruxolitinib.
Agomelatine	The metabolism of Ruxolitinib can be decreased when combined with Agomelatine.
Albendazole	The metabolism of Ruxolitinib can be decreased when combined with Albendazole.
Albutrepenonacog	Ruxolitinib may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Alclofenac	Alclofenac may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Aldesleukin	The metabolism of Ruxolitinib can be decreased when combined with Aldesleukin.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Ruxolitinib.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ruxolitinib.
Alfentanil	Ruxolitinib may increase the bradycardic activities of Alfentanil.
Allogeneic	The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Ruxolitinib.
Allopurinol	The risk or severity of adverse effects can be increased when Allopurinol is combined with Ruxolitinib.
Almasilate	Ruxolitinib may decrease the excretion rate of Almasilate which could result in a higher serum level.
Almotriptan	Almotriptan may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Alogliptin	Alogliptin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Alosetron	The metabolism of Ruxolitinib can be decreased when combined with Alosetron.
Alpelisib	The serum concentration of Ruxolitinib can be decreased when it is combined with Alpelisib.
Alprazolam	Alprazolam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Alteplase	The risk or severity of bleeding can be increased when Alteplase is combined with Ruxolitinib.
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Ruxolitinib.
Amantadine	Amantadine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Amikacin	Ruxolitinib may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride	Amiloride may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Aminoglutethimide	The metabolism of Ruxolitinib can be increased when combined with Aminoglutethimide.
Aminophenazone	Aminophenazone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Amiodarone	The metabolism of Ruxolitinib can be decreased when combined with Amiodarone.
Amitriptyline	Amitriptyline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Amlodipine	Ruxolitinib may increase the bradycardic activities of Amlodipine.
Ammonium chloride	Ammonium chloride may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Amobarbital	The metabolism of Ruxolitinib can be increased when combined with Amobarbital.
Amodiaquine	The metabolism of Ruxolitinib can be decreased when combined with Amodiaquine.
Amoxicillin	Amoxicillin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Amphetamine	Amphetamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Amphotericin B	Amphotericin B may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ampicillin	Ampicillin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Amprenavir	The metabolism of Ruxolitinib can be decreased when combined with Amprenavir.
Amrinone	Amrinone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Ruxolitinib.
Anagrelide	The risk or severity of bleeding can be increased when Anagrelide is combined with Ruxolitinib.
Anakinra	The metabolism of Ruxolitinib can be increased when combined with Anakinra.
Ancestim	Ruxolitinib may decrease the excretion rate of Ancestim which could result in a higher serum level.
Ancrod	The risk or severity of bleeding can be increased when Ancrod is combined with Ruxolitinib.
Anifrolumab	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Anifrolumab.
Anistreplase	The risk or severity of bleeding can be increased when Anistreplase is combined with Ruxolitinib.
Anthrax immune	The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ruxolitinib.
Anthrax vaccine	The risk or severity of infection can be increased when Anthrax vaccine is combined with Ruxolitinib.
Antihemophilic	Ruxolitinib may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
antilymphocyte	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Antilymphocyte immunoglobulin (horse).
Antipyrine	Antipyrine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Antithrombin Alfa	The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Ruxolitinib.
Antithrombin	Ruxolitinib may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Antithymocyte	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ruxolitinib.
Antrafenine	Antrafenine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Apalutamide	The metabolism of Ruxolitinib can be increased when combined with Apalutamide.
Apixaban	The risk or severity of bleeding can be increased when Apixaban is combined with Ruxolitinib.
Apremilast	The metabolism of Ruxolitinib can be increased when combined with Apremilast.
Aprepitant	The metabolism of Ruxolitinib can be decreased when combined with Aprepitant.
Ardeparin	The risk or severity of bleeding can be increased when Ardeparin is combined with Ruxolitinib.
Arformoterol	Arformoterol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Argatroban	The risk or severity of bleeding can be increased when Argatroban is combined with Ruxolitinib.
Armodafinil	The metabolism of Ruxolitinib can be increased when combined with Armodafinil.
Arsenic trioxide	The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ruxolitinib.
Artemether	The metabolism of Ruxolitinib can be decreased when combined with Artemether.
Articaine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Articaine.
Asciminib	The serum concentration of Ruxolitinib can be increased when it is combined with Asciminib.
Astemizole	The metabolism of Ruxolitinib can be decreased when combined with Astemizole.
A COVID-19 Vaccine	The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Ruxolitinib.
Asunaprevir	The metabolism of Ruxolitinib can be increased when combined with Asunaprevir.
Atazanavir	The metabolism of Ruxolitinib can be decreased when combined with Atazanavir.
Atenolol	Ruxolitinib may increase the bradycardic activities of Atenolol.
Atomoxetine	Atomoxetine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Atovaquone	The metabolism of Ruxolitinib can be decreased when combined with Atovaquone.
Auranofin	Auranofin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Aurothioglucose	Ruxolitinib may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
Avacopan	The metabolism of Ruxolitinib can be decreased when combined with Avacopan.
Avanafil	The serum concentration of Avanafil can be increased when it is combined with Ruxolitinib.
Avapritinib	The metabolism of Ruxolitinib can be decreased when combined with Avapritinib.
Avatrombopag	The metabolism of Ruxolitinib can be increased when combined with Avatrombopag.
Azacitidine	The risk or severity of adverse effects can be increased when Azacitidine is combined with Ruxolitinib.
Azathioprine	The risk or severity of adverse effects can be increased when Azathioprine is combined with Ruxolitinib.

Azelaic acid	Azelaic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Azelastine	The metabolism of Ruxolitinib can be decreased when combined with Azelastine.
Azithromycin	The metabolism of Ruxolitinib can be decreased when combined with Azithromycin.
Aztreonam	Aztreonam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Bacillus	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Ruxolitinib.
Bacillus calmette	The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Ruxolitinib.
Bacillus calm	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Ruxolitinib.
Bacitracin	Bacitracin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Baclofen	Baclofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Balsalazide	Balsalazide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Baricitinib	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Baricitinib.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Ruxolitinib.
BCG vaccine	The risk or severity of infection can be increased when BCG vaccine is combined with Ruxolitinib.
Beclomethasone	The metabolism of Ruxolitinib can be increased when combined with Beclomethasone dipropionate.
Belatacept	The risk or severity of adverse effects can be increased when Belatacept is combined with Ruxolitinib.
Belimumab	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Belimumab.
Belinostat	The risk or severity of adverse effects can be increased when Belinostat is combined with Ruxolitinib.
Belumosudil	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Belumosudil.
Belzutifan	The serum concentration of Ruxolitinib can be decreased when it is combined with Belzutifan.
Bemiparin	The risk or severity of bleeding can be increased when Bemiparin is combined with Ruxolitinib.
Bendamustine	The risk or severity of adverse effects can be increased when Bendamustine is combined with Ruxolitinib.
Bendroflumethiazide	Ruxolitinib may increase the bradycardic activities of Bendroflumethiazide.
Benorilate	Benorilate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Benoxaprofen	Benoxaprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Benserazide	Ruxolitinib may decrease the excretion rate of Benserazide which could result in a higher serum level.
Benzatropine	Benzatropine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Benznidazole	Ruxolitinib may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Benzocaine.
Benzthiazide	Benzthiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Benzydamine	Benzydamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Benzyl alcohol.
Bepotastine	Bepotastine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Bepridil	Ruxolitinib may increase the bradycardic activities of Bepridil.
Beractant	Ruxolitinib may increase the bradycardic activities of Beractant.
Berotralstat	The serum concentration of Ruxolitinib can be increased when it is combined with Berotralstat.
Betamethasone	The metabolism of Ruxolitinib can be increased when combined with Betamethasone.
Betamethasone	The metabolism of Ruxolitinib can be increased when combined with Betamethasone phosphate.
Betaxolol	Ruxolitinib may increase the bradycardic activities of Betaxolol.
Betrixaban	The risk or severity of bleeding can be increased when Betrixaban is combined with Ruxolitinib.
Bexarotene	The metabolism of Ruxolitinib can be increased when combined with Bexarotene.
Bicalutamide	The metabolism of Ruxolitinib can be decreased when combined with Bicalutamide.
Bicisate	Ruxolitinib may decrease the excretion rate of Bicisate which could result in a higher serum level.
Bifonazole	The metabolism of Ruxolitinib can be decreased when combined with Bifonazole.
Bimekizumab	The metabolism of Ruxolitinib can be increased when combined with Bimekizumab.
Bismuth subgallate	Ruxolitinib may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
Bisoprolol	Ruxolitinib may increase the bradycardic activities of Bisoprolol.
Bisoxatin	Ruxolitinib may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
Bivalirudin	The risk or severity of bleeding can be increased when Bivalirudin is combined with Ruxolitinib.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Ruxolitinib.
Blinatumomab	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Blinatumomab.
Boceprevir	The metabolism of Ruxolitinib can be decreased when combined with Boceprevir.
Bordetella pertussis	The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Ruxolitinib.
Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Ruxolitinib.
Bosentan	The metabolism of Ruxolitinib can be increased when combined with Bosentan.
Bosutinib	The metabolism of Ruxolitinib can be decreased when combined with Bosutinib.
Brentuximab vedotin	The metabolism of Ruxolitinib can be decreased when combined with Brentuximab vedotin.
Bretylium	Ruxolitinib may increase the bradycardic activities of Bretylium.
Brivaracetam	Brivaracetam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Brodalumab	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Brodalumab.
Bromazepam	Bromazepam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Bromotheophylline	Bromotheophylline may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Budesonide	The metabolism of Ruxolitinib can be increased when combined with Budesonide.
Bumadizone	Bumadizone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Bumetanide	Bumetanide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Bupivacaine.
Buprenorphine	The metabolism of Ruxolitinib can be decreased when combined with Buprenorphine.
Bupropion	Bupropion may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Buspirone	Buspirone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Busulfan	The risk or severity of adverse effects can be increased when Busulfan is combined with Ruxolitinib.
Butabarbital	Butabarbital may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Butacaine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Butacaine.
Butalbital	The metabolism of Ruxolitinib can be increased when combined with Butalbital.
Butamben	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Butamben.
Cabazitaxel	The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ruxolitinib.
Cabozantinib	The metabolism of Ruxolitinib can be decreased when combined with Cabozantinib.
Calcitriol	The metabolism of Ruxolitinib can be increased when combined with Calcitriol.
Calfactant	Ruxolitinib may increase the bradycardic activities of Calfactant.
Canagliflozin	Canagliflozin may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Canakinumab	The metabolism of Ruxolitinib can be increased when combined with Canakinumab.
Candesartan cilex	The metabolism of Ruxolitinib can be decreased when combined with Candesartan cilexetil.
Candicidin	The metabolism of Ruxolitinib can be decreased when combined with Candicidin.
Cangrelor	The risk or severity of bleeding can be increased when Cangrelor is combined with Ruxolitinib.
Cannabidiol	The metabolism of Ruxolitinib can be decreased when combined with Cannabidiol.
Carnosic acid	Carnosic acid may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Capecitabine	The serum concentration of Ruxolitinib can be increased when it is combined with Capecitabine.
Caplacizumab	The risk or severity of bleeding can be increased when Caplacizumab is combined with Ruxolitinib.
Capreomycin	Ruxolitinib may decrease the excretion rate of Capreomycin which could result in a higher serum level.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Capsaicin.
Carbamazepine	The metabolism of Ruxolitinib can be increased when combined with Carbamazepine.
Carbidopa	Carbidopa may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Carbimazole	The therapeutic efficacy of Carbimazole can be decreased when used in combination with Ruxolitinib.
Carboplatin	The risk or severity of adverse effects can be increased when Carboplatin is combined with Ruxolitinib.
Carfilzomib	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Carfilzomib.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Ruxolitinib.
Carprofen	Carprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Carvedilol	Ruxolitinib may increase the bradycardic activities of Carvedilol.
Cefaclor	Cefaclor may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefadroxil	Cefadroxil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefalotin	Cefalotin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefamandole	Cefamandole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.

Cefapirin	Cefapirin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefazolin	Cefazolin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefdinir	Cefdinir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefditoren	Cefditoren may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefepime	Cefepime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefmenoxime	Cefmenoxime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefmetazole	Cefmetazole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefonicid	Cefonicid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefoperazone	Cefoperazone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ceforanide	Ceforanide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefotaxime	Cefotaxime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefotetan	Cefotetan may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefotiam	Cefotiam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefoxitin	Cefoxitin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefpiramide	Cefpiramide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefpirome	Cefpirome may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefpodoxime	Cefpodoxime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefprozil	Cefprozil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefradine	The metabolism of Ruxolitinib can be increased when combined with Cefradine.
Ceftaroline fosamil	Ceftaroline fosamil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ceftazidime	Ceftazidime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ceftibuten	Ceftibuten may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ceftizoxime	Ceftizoxime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ceftobiprole	Ceftobiprole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ceftolozane	Ruxolitinib may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
Ceftriaxone	Ceftriaxone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefuroxime	Cefuroxime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Celecoxib	Celecoxib may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Celiprolol	Ruxolitinib may increase the bradycardic activities of Celiprolol.
Cenobamate	The serum concentration of Ruxolitinib can be decreased when it is combined with Cenobamate.
Cephalexin	The metabolism of Ruxolitinib can be decreased when combined with Cephalexin.
Cephaloglycin	Cephaloglycin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ceritinib	Ruxolitinib may increase the bradycardic activities of Ceritinib.
Cerivastatin	The metabolism of Ruxolitinib can be increased when combined with Cerivastatin.
Certolizumab	The metabolism of Ruxolitinib can be increased when combined with Certolizumab pegol.
Cetirizine	Cetirizine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cevimeline	Cevimeline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Chloral hydrate	Chloral hydrate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Ruxolitinib.
Chloramphenicol	The metabolism of Ruxolitinib can be decreased when combined with Chloramphenicol.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Chloroprocaine.
Chloroquine	Chloroquine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Chlorothiazide	Chlorothiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Chloroxylenol	Ruxolitinib may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.
Chlorpromazine	The metabolism of Ruxolitinib can be increased when combined with Chlorpromazine.
Chlorpropamide	Chlorpropamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Chlorthalidone	Chlorthalidone may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Chlorzoxazone	Chlorzoxazone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Choline C 11	Ruxolitinib may decrease the excretion rate of Choline C 11 which could result in a higher serum level.
Choline magnesium	Choline magnesium trisalicylate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Choline salicylate	Ruxolitinib may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
Chondroitin sulfate	Ruxolitinib may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
Chromic chloride	Ruxolitinib may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
Chromic nitrate	Ruxolitinib may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
Chromium	Ruxolitinib may decrease the excretion rate of Chromium which could result in a higher serum level.
Chromium gluconate	Ruxolitinib may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
Chromium nicotinate	Ruxolitinib may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
Chromous sulfate	Ruxolitinib may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
Ciclesonide	The risk or severity of adverse effects can be increased when Ciclesonide is combined with Ruxolitinib.
Cidofovir	Cidofovir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cilostazol	The risk or severity of bleeding can be increased when Cilostazol is combined with Ruxolitinib.
Cimetidine	The metabolism of Ruxolitinib can be decreased when combined with Cimetidine.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Cinchocaine.
Cinnarizine	Ruxolitinib may increase the bradycardic activities of Cinnarizine.
Ciprofloxacin	The metabolism of Ruxolitinib can be decreased when combined with Ciprofloxacin.
Cisapride	The metabolism of Ruxolitinib can be decreased when combined with Cisapride.
Cisplatin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Ruxolitinib.
Citalopram	The metabolism of Ruxolitinib can be decreased when combined with Citalopram.
Cladribine	The risk or severity of adverse effects can be increased when Cladribine is combined with Ruxolitinib.
Clarithromycin	The metabolism of Ruxolitinib can be decreased when combined with Clarithromycin.
Clevidipine	Ruxolitinib may increase the bradycardic activities of Clevidipine.
Clobazam	The metabolism of Ruxolitinib can be increased when combined with Clobazam.
Clobetasol prop	The metabolism of Ruxolitinib can be increased when combined with Clobetasol propionate.
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Ruxolitinib.
Clofazimine	The metabolism of Ruxolitinib can be decreased when combined with Clofazimine.
Clofibrate	The metabolism of Ruxolitinib can be increased when combined with Clofibrate.
Clomipramine	Clomipramine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Clonazepam	Clonazepam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Clonidine	Ruxolitinib may increase the bradycardic activities of Clonidine.
Clopidogrel	The metabolism of Ruxolitinib can be decreased when combined with Clopidogrel.
Clorazepic acid	Clorazepic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Clostridium	The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ruxolitinib.
Clove oil	Ruxolitinib may decrease the excretion rate of Clove oil which could result in a higher serum level.
Clozapine	The risk or severity of neutropenia can be increased when Ruxolitinib is combined with Clozapine.
Cobicistat	The metabolism of Ruxolitinib can be decreased when combined with Cobicistat.
Cobimetinib	The metabolism of Ruxolitinib can be decreased when combined with Cobimetinib.
Cocaine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Cocaine.
Colchicine	Colchicine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Colistimethate	Colistimethate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Colistin	Ruxolitinib may decrease the excretion rate of Colistin which could result in a higher serum level.
Conivaptan	The metabolism of Ruxolitinib can be decreased when combined with Conivaptan.
Conjugated estrogens	Conjugated estrogens may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Corifollitropin alfa	Ruxolitinib may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.
Corticotropin	The metabolism of Ruxolitinib can be increased when combined with Corticotropin.
Cortisone acetate	The metabolism of Ruxolitinib can be increased when combined with Cortisone acetate.
Corynebacterium	The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ruxolitinib.
Crizotinib	The metabolism of Ruxolitinib can be decreased when combined with Crizotinib.
Curcumin	The metabolism of Ruxolitinib can be decreased when combined with Curcumin.
Cyanocobalamin	The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ruxolitinib.
Cyclandelate	Ruxolitinib may increase the bradycardic activities of Cyclandelate.

Cyclizine	The metabolism of Ruxolitinib can be decreased when combined with Cyclizine.
Cyclopenthiazide	Cyclopenthiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Cyclophosphamide	The metabolism of Ruxolitinib can be increased when combined with Cyclophosphamide.
Cyclosporine	Ruxolitinib may increase the immunosuppressive activities of Cyclosporine.
Cyclothiazide	Cyclothiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Cyproterone ace	The metabolism of Ruxolitinib can be decreased when combined with Cyproterone acetate.
Cytarabine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Ruxolitinib.
Dabigatran	The risk or severity of bleeding can be increased when Dabigatran is combined with Ruxolitinib.
Dabigatran et	Dabigatran etexilate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Dabrafenib	The serum concentration of Ruxolitinib can be decreased when it is combined with Dabrafenib.
Dacarbazine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Ruxolitinib.
Dacomitinib	The metabolism of Ruxolitinib can be decreased when combined with Dacomitinib.
Dactinomycin	The risk or severity of adverse effects can be increased when Dactinomycin is combined with Ruxolitinib.
Dalfampridine	Dalfampridine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Dalfopristin	The metabolism of Ruxolitinib can be decreased when combined with Dalfopristin.
Dalteparin	The risk or severity of bleeding can be increased when Dalteparin is combined with Ruxolitinib.
Danaparoid	The risk or severity of bleeding can be increased when Danaparoid is combined with Ruxolitinib.
Danazol	The metabolism of Ruxolitinib can be decreased when combined with Danazol.
Dapagliflozin	Dapagliflozin may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Dapsone	The metabolism of Ruxolitinib can be increased when combined with Dapsone.
Daptomycin	Daptomycin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Darbepoetin	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ruxolitinib.
Darunavir	The serum concentration of Ruxolitinib can be increased when it is combined with Darunavir.
Dasatinib	The metabolism of Ruxolitinib can be decreased when combined with Dasatinib.
Daunorubicin	The metabolism of Ruxolitinib can be decreased when combined with Daunorubicin.
Decitabine	The risk or severity of adverse effects can be increased when Decitabine is combined with Ruxolitinib.
Deferasirox	The metabolism of Ruxolitinib can be increased when combined with Deferasirox.
Deferiprone	Deferiprone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Defibrotide	The risk or severity of bleeding can be increased when Defibrotide is combined with Ruxolitinib.
Deflazacort	The metabolism of Ruxolitinib can be increased when combined with Deflazacort.
Delafloxacin	The metabolism of Ruxolitinib can be increased when combined with Delafloxacin.
Delavirdine	The metabolism of Ruxolitinib can be decreased when combined with Delavirdine.
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Ruxolitinib.
Desipramine	The metabolism of Ruxolitinib can be decreased when combined with Desipramine.
Desirudin	The risk or severity of bleeding can be increased when Desirudin is combined with Ruxolitinib.
Desmopressin	Desmopressin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Desogestrel	The metabolism of Ruxolitinib can be decreased when combined with Desogestrel.
Desoximetasone	The risk or severity of adverse effects can be increased when Desoximetasone is combined with Ruxolitinib.
Desvenlafaxine	The metabolism of Ruxolitinib can be decreased when combined with Desvenlafaxine.
Deucravacitinib	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Deucravacitinib.
Deutetrabenazine	Ruxolitinib may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
Dexamethasone	The metabolism of Ruxolitinib can be increased when combined with Dexamethasone.
Dexamethasone acetate	The metabolism of Ruxolitinib can be increased when combined with Dexamethasone acetate.
Dexibuprofen	Dexibuprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Dexketoprofen	Dexketoprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Dexmedetomidine	Ruxolitinib may increase the bradycardic activities of Dexmedetomidine.
Dexpanthenol	Ruxolitinib may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
Dexrazoxane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ruxolitinib.
Dextran	Ruxolitinib may decrease the excretion rate of Dextran which could result in a higher serum level.
Dextromethorphan	The metabolism of Ruxolitinib can be decreased when combined with Dextromethorphan.
Dextropropoxyph	The metabolism of Ruxolitinib can be decreased when combined with Dextropropoxyphene.
Diacerein	The metabolism of Ruxolitinib can be decreased when combined with Diacerein.
Diatrizoate	Diatrizoate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Diazepam	Diazepam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Dichlorobenzyl	Ruxolitinib may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
Diclofenac	Diclofenac may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Diclofenamide	Diclofenamide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Dicloxacillin	The metabolism of Ruxolitinib can be increased when combined with Dicloxacillin.
Dicoumarol	The risk or severity of bleeding can be increased when Dicoumarol is combined with Ruxolitinib.
Dicyclomine	Dicyclomine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Didanosine	Didanosine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Dienogest	Ruxolitinib may decrease the excretion rate of Dienogest which could result in a higher serum level.
Diethylstilbestrol	The metabolism of Ruxolitinib can be decreased when combined with Diethylstilbestrol.
Diflunisal	Diflunisal may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Difluocortolone	The metabolism of Ruxolitinib can be increased when combined with Difluocortolone.
Digoxin	Ruxolitinib may increase the bradycardic activities of Digoxin.
Dihydroergocornine	The metabolism of Ruxolitinib can be decreased when combined with Dihydroergocornine.
Dihydroergocristine	The metabolism of Ruxolitinib can be decreased when combined with Dihydroergocristine.
Dihydroergotamine	The metabolism of Ruxolitinib can be decreased when combined with Dihydroergotamine.
Dihydrostreptomycin	Dihydrostreptomycin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Diltiazem	Ruxolitinib may increase the bradycardic activities of Diltiazem.
Dimercaprol	Dimercaprol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Dimethyl fumarate	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Dimethyl fumarate.
Dimethyl sulfoxide	The metabolism of Ruxolitinib can be decreased when combined with Dimethyl sulfoxide.
Dinutuximab	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Dinutuximab.
Diosmin	The metabolism of Ruxolitinib can be decreased when combined with Diosmin.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Diphenhydramine.
Dipyridamole	The risk or severity of bleeding can be increased when Dipyridamole is combined with Ruxolitinib.
Diroximel fumarate	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Diroximel fumarate.
Disopyramide	Disopyramide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
DL-Methylephedrine	Ruxolitinib may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
Dobutamine	Dobutamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Docetaxel	The metabolism of Ruxolitinib can be decreased when combined with Docetaxel.
Doconexent	The metabolism of Ruxolitinib can be decreased when combined with Doconexent.
Donepezil	Ruxolitinib may increase the bradycardic activities of Donepezil.
Dopamine	Dopamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Doripenem	Doripenem may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Doxacurium	Doxacurium may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Doxazosin	The metabolism of Ruxolitinib can be decreased when combined with Doxazosin.
Doxepin	Doxepin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Doxorubicin	The metabolism of Ruxolitinib can be decreased when combined with Doxorubicin.
Doxycycline	Doxycycline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Dronabinol	The metabolism of Ruxolitinib can be decreased when combined with Dronabinol.
Dronedarone	The serum concentration of Ruxolitinib can be increased when it is combined with Dronedarone.
Drospirenone	The metabolism of Ruxolitinib can be decreased when combined with Drospirenone.
Drotrecogin alfa	The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ruxolitinib.
Droxidopa	Droxidopa may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Duloxetine	Duloxetine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Duvelisib	The metabolism of Ruxolitinib can be decreased when combined with Duvelisib.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Dyclonine.

Dyphylline	Dyphylline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ebastine	The metabolism of Ruxolitinib can be decreased when combined with Ebastine.
Ebola Zaire	The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Ruxolitinib.
Echinacea	The metabolism of Ruxolitinib can be increased when combined with Echinacea.
Eculizumab	The risk or severity of adverse effects can be increased when Eculizumab is combined with Ruxolitinib.
Edetic acid	The risk or severity of bleeding can be increased when Edetic acid is combined with Ruxolitinib.
Edoxaban	Ruxolitinib may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Edrophonium	Edrophonium may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Ruxolitinib.
Efavirenz	The metabolism of Ruxolitinib can be decreased when combined with Efavirenz.
Eletriptan	The metabolism of Ruxolitinib can be decreased when combined with Eletriptan.
Elexacaftor	The metabolism of Ruxolitinib can be decreased when combined with Elexacaftor.
Elvitegravir	The metabolism of Ruxolitinib can be decreased when combined with Elvitegravir.
Emapalumab	The metabolism of Ruxolitinib can be increased when combined with Emapalumab.
Enalaprilat	Ruxolitinib may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
Enasidenib	The metabolism of Ruxolitinib can be increased when combined with Enasidenib.
Enoxaparin	The risk or severity of bleeding can be increased when Enoxaparin is combined with Ruxolitinib.
Enzalutamide	The serum concentration of Ruxolitinib can be decreased when it is combined with Enzalutamide.
Epinephrine	The metabolism of Ruxolitinib can be decreased when combined with Epinephrine.
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Ruxolitinib.
Eplerenone	Eplerenone may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Epoprostenol	The risk or severity of bleeding can be increased when Epoprostenol is combined with Ruxolitinib.
Eptifibatide	The risk or severity of bleeding can be increased when Eptifibatide is combined with Ruxolitinib.
Erdafitinib	The metabolism of Erdafitinib can be decreased when combined with Ruxolitinib.
Ergotamine	The metabolism of Ruxolitinib can be decreased when combined with Ergotamine.
Eribulin	The risk or severity of adverse effects can be increased when Eribulin is combined with Ruxolitinib.
Erlotinib	The metabolism of Ruxolitinib can be decreased when combined with Erlotinib.
Ertapenem	Ertapenem may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ertugliflozin	Ertugliflozin may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Erythromycin	The metabolism of Ruxolitinib can be decreased when combined with Erythromycin.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ruxolitinib.
Esketamine	The metabolism of Ruxolitinib can be increased when combined with Esketamine.
Eslicarbazepine	The metabolism of Ruxolitinib can be increased when combined with Eslicarbazepine.
Eslicarbazepine acetate	The metabolism of Ruxolitinib can be increased when combined with Eslicarbazepine acetate.
Esmolol	Ruxolitinib may increase the bradycardic activities of Esmolol.
Estazolam	Estazolam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Estetrol	The metabolism of Ruxolitinib can be decreased when combined with Estetrol.
Estradiol	Estradiol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Estradiol acetate	The metabolism of Ruxolitinib can be increased when combined with Estradiol acetate.
Estradiol benzoate	The metabolism of Ruxolitinib can be increased when combined with Estradiol benzoate.
Estradiol cypionate	The metabolism of Ruxolitinib can be increased when combined with Estradiol cypionate.
Estradiol dienanthate	The metabolism of Ruxolitinib can be increased when combined with Estradiol dienanthate.
Estradiol valerate	The metabolism of Ruxolitinib can be increased when combined with Estradiol valerate.
Estramustine	The risk or severity of adverse effects can be increased when Estramustine is combined with Ruxolitinib.
Estrone sulfate	The metabolism of Ruxolitinib can be decreased when combined with Estrone sulfate.
Eszopiclone	Eszopiclone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Etacrynic acid	Etacrynic acid may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Etafedrine	Ruxolitinib may decrease the excretion rate of Etafedrine which could result in a higher serum level.
Etanercept	The metabolism of Ruxolitinib can be increased when combined with Etanercept.
Ethambutol	The metabolism of Ruxolitinib can be decreased when combined with Ethambutol.
Ethanol	The metabolism of Ruxolitinib can be increased when combined with Ethanol.
Ethinylestradiol	The metabolism of Ruxolitinib can be decreased when combined with Ethinylestradiol.
Ethosuximide	Ruxolitinib may increase the bradycardic activities of Ethosuximide.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Etidocaine.
Etodolac	Etodolac may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Etomidate	Etomidate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Etonogestrel	Etonogestrel may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Etoposide	The risk or severity of adverse effects can be increased when Etoposide is combined with Ruxolitinib.
Etoricoxib	The metabolism of Ruxolitinib can be decreased when combined with Etoricoxib.
Etravirine	The metabolism of Ruxolitinib can be increased when combined with Etravirine.
Eucalyptus oil	Ruxolitinib may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Everolimus	The risk or severity of adverse effects can be increased when Everolimus is combined with Ruxolitinib.
Ezogabine	Ezogabine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Famtozinameran	The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Ruxolitinib.
Felbamate	The metabolism of Ruxolitinib can be increased when combined with Felbamate.
Felodipine	Ruxolitinib may increase the bradycardic activities of Felodipine.
Fenbufen	Fenbufen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Fenofibrate	The metabolism of Ruxolitinib can be decreased when combined with Fenofibrate.
Fenofibric acid	Ruxolitinib may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
Fenoldopam	Fenoldopam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Fenoprofen	Fenoprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Fentanyl	Ruxolitinib may increase the bradycardic activities of Fentanyl.
Fesoterodine	Fesoterodine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Fexinidazole	The metabolism of Ruxolitinib can be decreased when combined with Fexinidazole.
Filgotinib	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Filgotinib.
Finerenone	Finerenone may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Fingolimod	Ruxolitinib may increase the immunosuppressive activities of Fingolimod.
Flavoxate	Flavoxate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Flecainide	The metabolism of Ruxolitinib can be decreased when combined with Flecainide.
Floctafenine	Floctafenine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Florbetaben (18F)	Ruxolitinib may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
Florbetapir (18F)	Ruxolitinib may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
Floxuridine	The metabolism of Ruxolitinib can be decreased when combined with Floxuridine.
Flucloxacillin	The metabolism of Ruxolitinib can be increased when combined with Flucloxacillin.
Fluconazole	The serum concentration of Ruxolitinib can be increased when it is combined with Fluconazole.
Flucytosine	The risk or severity of adverse effects can be increased when Flucytosine is combined with Ruxolitinib.
Fludarabine	The risk or severity of adverse effects can be increased when Fludarabine is combined with Ruxolitinib.
Fludeoxyglucose (18F)	Ruxolitinib may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
Fludrocortisone	The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ruxolitinib.
Fluindione	The risk or severity of bleeding can be increased when Fluindione is combined with Ruxolitinib.
Flumazenil	Flumazenil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Flunarizine	Ruxolitinib may increase the bradycardic activities of Flunarizine.
Flunisolide	The metabolism of Ruxolitinib can be increased when combined with Flunisolide.
Flunitrazepam	The metabolism of Ruxolitinib can be decreased when combined with Flunitrazepam.
Fluocinolone acetonide	The metabolism of Ruxolitinib can be increased when combined with Fluocinolone acetonide.
Fluocinonide	The metabolism of Ruxolitinib can be increased when combined with Fluocinonide.
Fluocortolone	The metabolism of Ruxolitinib can be increased when combined with Fluocortolone.
Fluorometholone	The risk or severity of adverse effects can be increased when Fluorometholone is combined with Ruxolitinib.
Fluorouracil	The metabolism of Ruxolitinib can be decreased when combined with Fluorouracil.

Fluoxetine	The metabolism of Ruxolitinib can be decreased when combined with Fluoxetine.
Flupentixol	The risk or severity of myelosuppression can be increased when Flupentixol is combined with Ruxolitinib.
Fluprednisolone	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Fluprednisolone.
Flurazepam	Flurazepam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Flurbiprofen	Flurbiprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Fluspirilene	Ruxolitinib may increase the bradycardic activities of Fluspirilene.
Flutamide	Flutamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Fluticasone	The metabolism of Ruxolitinib can be increased when combined with Fluticasone.
Fluticasone fur	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Fluticasone furoate.
Fluticasone prop	The metabolism of Ruxolitinib can be decreased when combined with Fluticasone propionate.
Fluvastatin	The metabolism of Ruxolitinib can be decreased when combined with Fluvastatin.
Fluvoxamine	The metabolism of Ruxolitinib can be decreased when combined with Fluvoxamine.
Folic acid	Folic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Follitropin	The therapeutic efficacy of Follitropin can be decreased when used in combination with Ruxolitinib.
Fomepizole	Fomepizole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Fondaparinux	Fondaparinux may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Formestane	The metabolism of Ruxolitinib can be increased when combined with Formestane.
Formoterol	The metabolism of Ruxolitinib can be decreased when combined with Formoterol.
Fosamprenavir	The metabolism of Ruxolitinib can be decreased when combined with Fosamprenavir.
Fosaprepitant	The metabolism of Ruxolitinib can be increased when combined with Fosaprepitant.
Foscarnet	Foscarnet may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Fosfomycin	Fosfomycin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Fosinopril	Fosinopril may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Fosnetupitant	The metabolism of Ruxolitinib can be decreased when combined with Fosnetupitant.
Fosphenytoin	The metabolism of Ruxolitinib can be increased when combined with Fosphenytoin.
Fostamatinib	The metabolism of Ruxolitinib can be decreased when combined with Fostamatinib.
Framycetin	Framycetin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Furosemide	Furosemide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Fusidic acid	The metabolism of Ruxolitinib can be decreased when combined with Fusidic acid.
Gabapentin enacarbil	Gabapentin enacarbil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Gadobenic acid	Gadobenic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Gadodiamide	Gadodiamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Gadofosveset trisodium	Gadofosveset trisodium may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Gadopentetic acid	Gadopentetic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Gadoteric acid	Ruxolitinib may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
Gadoteridol	Gadoteridol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Galantamine	Ruxolitinib may increase the bradycardic activities of Galantamine.
Gallium nitrate	The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Ruxolitinib.
Ganciclovir	Ganciclovir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Ruxolitinib.
Gemfibrozil	The metabolism of Ruxolitinib can be decreased when combined with Gemfibrozil.
Gemtuzumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ruxolitinib.
Gentamicin	Ruxolitinib may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Gilteritinib	The metabolism of Ruxolitinib can be decreased when combined with Gilteritinib.
Gimeracil	Ruxolitinib may decrease the excretion rate of Gimeracil which could result in a higher serum level.
Ginkgo biloba	The metabolism of Ruxolitinib can be decreased when combined with Ginkgo biloba.
Givosiran	Givosiran may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Glatiramer	The risk or severity of adverse effects can be increased when Glatiramer is combined with Ruxolitinib.
Glecaprevir	The metabolism of Ruxolitinib can be decreased when combined with Glecaprevir.
Gliclazide	The metabolism of Ruxolitinib can be decreased when combined with Gliclazide.
Glimepiride	The metabolism of Ruxolitinib can be decreased when combined with Glimepiride.
Glipizide	Glipizide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Gliquidone	The metabolism of Ruxolitinib can be decreased when combined with Gliquidone.
Glyburide	The metabolism of Ruxolitinib can be decreased when combined with Glyburide.
Glycerol phenyl	The metabolism of Ruxolitinib can be increased when combined with Glycerol phenylbutyrate.
Golimumab	The metabolism of Ruxolitinib can be increased when combined with Golimumab.
Golodirsen	Ruxolitinib may decrease the excretion rate of Golodirsen which could result in a higher serum level.
Goserelin	Goserelin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Griseofulvin	The metabolism of Ruxolitinib can be increased when combined with Griseofulvin.
Guanethidine	Guanethidine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Guanfacine	Ruxolitinib may increase the bradycardic activities of Guanfacine.
Guselkumab	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Guselkumab.
Haemophilus	The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Ruxolitinib.
Haloperidol	The serum concentration of Haloperidol can be increased when it is combined with Ruxolitinib.
Halothane	The metabolism of Ruxolitinib can be decreased when combined with Halothane.
Heparin	The risk or severity of bleeding can be increased when Heparin is combined with Ruxolitinib.
Hepatitis A Vaccine	The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ruxolitinib.
Hepatitis B Vacc	The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ruxolitinib.
Human adenovirus	The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Ruxolitinib.
Hydralazine	The metabolism of Ruxolitinib can be decreased when combined with Hydralazine.
Hydrochlorothiazide	Hydrochlorothiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Hydrocortamate	The metabolism of Ruxolitinib can be increased when combined with Hydrocortamate.
Hydrocortisone	The metabolism of Ruxolitinib can be increased when combined with Hydrocortisone.
Hydrocortisone ace	The metabolism of Ruxolitinib can be increased when combined with Hydrocortisone acetate.
Hydrocortisone bu	The metabolism of Ruxolitinib can be increased when combined with Hydrocortisone butyrate.
Hydrocortisone suc	The metabolism of Ruxolitinib can be increased when combined with Hydrocortisone succinate.
Hydroflumethiazide	Hydroflumethiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Hydromorphone	Hydromorphone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Hydroxocobalamin	Hydroxocobalamin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Hydroxychloroquine	The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Ruxolitinib.
Hydroxyethyl Starch	Ruxolitinib may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
Hydroxyurea	The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Ruxolitinib.
Ibritumomab tiu	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ruxolitinib.
Ibrutinib	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ibrutinib.
Ibuprofen	Ibuprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ibutilide	Ibutilide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Icatibant	Icatibant may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Icosapent	Icosapent may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Icosapent ethyl	The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Ruxolitinib.
Idarubicin	The risk or severity of adverse effects can be increased when Idarubicin is combined with Ruxolitinib.
Idarucizumab	Ruxolitinib may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
Idebenone	Ruxolitinib may decrease the excretion rate of Idebenone which could result in a higher serum level.
Idelalisib	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Idelalisib.
Ifosfamide	The metabolism of Ruxolitinib can be increased when combined with Ifosfamide.
Iloprost	The risk or severity of bleeding can be increased when Iloprost is combined with Ruxolitinib.
Imatinib	The serum concentration of Ruxolitinib can be increased when it is combined with Imatinib.
Imipramine	Imipramine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Indapamide	Indapamide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Indigotindisulfonic acid	Ruxolitinib may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
Indinavir	The metabolism of Ruxolitinib can be decreased when combined with Indinavir.

Inositol	Ruxolitinib may decrease the excretion rate of Inositol which could result in a higher serum level.
Inotersen	Inotersen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Interferon alfa-2a	The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Ruxolitinib.
Interferon alfa-2b	The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ruxolitinib.
Interferon alfa-n1	The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ruxolitinib.
Interferon alfa-n3	The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ruxolitinib.
Interferon alfacon-1	The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ruxolitinib.
Interferon beta-1b	The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ruxolitinib.
Interferon gamm	The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ruxolitinib.
Iobenguane sulfate I	Ruxolitinib may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Iodixanol	Iodixanol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ioflupane I-123	Ioflupane I-123 may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Iopromide	Ruxolitinib may decrease the excretion rate of Iopromide which could result in a higher serum level.
Iothalamic acid	Ruxolitinib may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
Ioversol	Ruxolitinib may decrease the excretion rate of Ioversol which could result in a higher serum level.
Ioxilan	Ruxolitinib may decrease the excretion rate of Ioxilan which could result in a higher serum level.
Ipecac	Ruxolitinib may decrease the excretion rate of Ipecac which could result in a higher serum level.
Ipilimumab	Ipilimumab may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Irbesartan	The metabolism of Ruxolitinib can be decreased when combined with Irbesartan.
Irinotecan	The risk or severity of adverse effects can be increased when Irinotecan is combined with Ruxolitinib.
Isavuconazole	The metabolism of Ruxolitinib can be increased when combined with Isavuconazole.
Isavuconazonium	The metabolism of Ruxolitinib can be increased when combined with Isavuconazonium.
Isoniazid	The metabolism of Ruxolitinib can be decreased when combined with Isoniazid.
Isosorbide	Isosorbide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide monon	Isosorbide mononitrate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Isosulfan blue	Ruxolitinib may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
Isotretinoin	Isotretinoin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Isoxicam	Isoxicam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Isradipine	Ruxolitinib may increase the bradycardic activities of Isradipine.
Istradefylline	The metabolism of Istradefylline can be decreased when combined with Ruxolitinib.
Itraconazole	The metabolism of Ruxolitinib can be decreased when combined with Itraconazole.
Ivabradine	Ruxolitinib may increase the bradycardic activities of Ivabradine.
Ivacaftor	The metabolism of Ruxolitinib can be decreased when combined with Ivacaftor.
Ivosidenib	The metabolism of Ruxolitinib can be increased when combined with Ivosidenib.
Ixabepilone	The risk or severity of adverse effects can be increased when Ixabepilone is combined with Ruxolitinib.
Ixazomib	Ruxolitinib may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Ixekizumab	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ixekizumab.
Janssen COVID-19	The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Ruxolitinib.
Japencephalitis virus	The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Ruxolitinib.
Kanamycin	Ruxolitinib may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Ketamine	Ketamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ketazolam	The metabolism of Ruxolitinib can be decreased when combined with Ketazolam.
Ketoconazole	The metabolism of Ruxolitinib can be decreased when combined with Ketoconazole.
Ketoprofen	Ketoprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ketorolac	Ketorolac may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Labetalol	Ruxolitinib may increase the bradycardic activities of Labetalol.
Lacidipine	Ruxolitinib may increase the bradycardic activities of Lacidipine.
Lacosamide	Ruxolitinib may increase the bradycardic activities of Lacosamide.
Lamivudine	Lamivudine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Lamotrigine	Ruxolitinib may increase the bradycardic activities of Lamotrigine.
Lanreotide	Ruxolitinib may increase the bradycardic activities of Lanreotide.
Lansoprazole	The metabolism of Ruxolitinib can be decreased when combined with Lansoprazole.
Lapatinib	The metabolism of Ruxolitinib can be decreased when combined with Lapatinib.
Latamoxef	Latamoxef may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ledipasvir	Ruxolitinib may decrease the excretion rate of Ledipasvir which could result in a higher serum level.
Lefamulin	The serum concentration of Ruxolitinib can be increased when it is combined with Lefamulin.
Leflunomide	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Leflunomide.
Lenalidomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Ruxolitinib.
Lepirudin	The risk or severity of bleeding can be increased when Lepirudin is combined with Ruxolitinib.
Lercanidipine	Ruxolitinib may increase the bradycardic activities of Lercanidipine.
Lesinurad	The metabolism of Ruxolitinib can be increased when combined with Lesinurad.
Letermovir	The metabolism of Ruxolitinib can be decreased when combined with Letermovir.
Leuprolide	Leuprolide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Levobetaxolol	Ruxolitinib may increase the bradycardic activities of Levobetaxolol.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Levobupivacaine.
Levocarnitine	Levocarnitine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Levocetirizine	Levocetirizine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Levofloxacin	Levofloxacin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Levoketoconazole	The metabolism of Ruxolitinib can be decreased when combined with Levoketoconazole.
Levomenthol	Ruxolitinib may increase the bradycardic activities of Levomenthol.
Levomilnacipran	Ruxolitinib may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Levosalbutamol	Ruxolitinib may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
Levothyroxine	The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Ruxolitinib.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Lidocaine.
Lidoflazine	Ruxolitinib may increase the bradycardic activities of Lidoflazine.
Linagliptin	The metabolism of Ruxolitinib can be decreased when combined with Linagliptin.
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Ruxolitinib.
Liothyronine	The therapeutic efficacy of Liothyronine can be decreased when used in combination with Ruxolitinib.
Liotrix	The therapeutic efficacy of Liotrix can be decreased when used in combination with Ruxolitinib.
Lipegfilgrastim	Ruxolitinib may increase the myelosuppressive activities of Lipegfilgrastim.
Lisinopril	Lisinopril may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Lithium carbonate	Ruxolitinib may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.

Lithium citrate	Lithium citrate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Lixisenatide	Ruxolitinib may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
Lofexidine	Lofexidine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Lomitapide	The metabolism of Ruxolitinib can be decreased when combined with Lomitapide.
Lomustine	The risk or severity of adverse effects can be increased when Lomustine is combined with Ruxolitinib.
Lonafarnib	The metabolism of Ruxolitinib can be decreased when combined with Lonafarnib.
Loperamide	Ruxolitinib may increase the bradycardic activities of Loperamide.
Lopinavir	The metabolism of Ruxolitinib can be decreased when combined with Lopinavir.
Loracarbef	Loracarbef may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Lorazepam	Lorazepam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Lorcaserin	Lorcaserin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Lorlatinib	The metabolism of Ruxolitinib can be increased when combined with Lorlatinib.
Lornoxicam	Lornoxicam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Lorpiprazole	Ruxolitinib may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.
Losartan	The metabolism of Ruxolitinib can be decreased when combined with Losartan.
Lovastatin	The metabolism of Ruxolitinib can be decreased when combined with Lovastatin.
Loxoprofen	Loxoprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Lubiprostone	Lubiprostone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Lucinactant	Ruxolitinib may increase the bradycardic activities of Lucinactant.
Lumacaftor	The metabolism of Ruxolitinib can be increased when combined with Lumacaftor.
Lumiracoxib	Lumiracoxib may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Lynestrenol	The metabolism of Lynestrenol can be decreased when combined with Ruxolitinib.
Macitentan	Ruxolitinib may decrease the excretion rate of Macitentan which could result in a higher serum level.
Magnesium	The serum concentration of Magnesium can be decreased when it is combined with Ruxolitinib.
Magnesium carb	Ruxolitinib may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
Magnesium chlo	Ruxolitinib may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
Magnesium hyd	Ruxolitinib may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Magnesium sulfate	Ruxolitinib may increase the bradycardic activities of Magnesium sulfate.
Magnesium tris	Ruxolitinib may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Mangafodipir	Mangafodipir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Manidipine	Ruxolitinib may increase the bradycardic activities of Manidipine.
Mannitol	Mannitol may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Maprotiline	Maprotiline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Mavacamten	The serum concentration of Ruxolitinib can be decreased when it is combined with Mavacamten.
Measles virus vaccine	The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Ruxolitinib.
Mecamylamine	Mecamylamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Mechlorethamine	The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Ruxolitinib.
Meclofenamic acid	Meclofenamic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Medroxyprogester	The metabolism of Ruxolitinib can be increased when combined with Medroxyprogesterone acetate.
Mefenamic acid	Mefenamic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Megestrol acetate	Megestrol acetate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Meloxicam.
Melphalan	The risk or severity of adverse effects can be increased when Melphalan is combined with Ruxolitinib.
Memantine	Memantine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Meningococcal	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Ruxolitinib.
Meperidine	The metabolism of Ruxolitinib can be decreased when combined with Meperidine.
Mephenytoin	The metabolism of Ruxolitinib can be decreased when combined with Mephenytoin.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Mepivacaine.
Mepolizumab	The risk or severity of adverse effects can be increased when Mepolizumab is combined with Ruxolitinib.
Meprednisone	The metabolism of Ruxolitinib can be increased when combined with Meprednisone.
Mercaptopurine	The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Ruxolitinib.
Meropenem	Meropenem may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Mesalazine	Mesalazine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Mestranol	The metabolism of Ruxolitinib can be decreased when combined with Mestranol.
Metamfetamine	Metamfetamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Metamizole	The risk or severity of myelosuppression can be increased when Metamizole is combined with Ruxolitinib.
Metaxalone	Metaxalone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Metformin	Metformin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Methadone	The metabolism of Ruxolitinib can be decreased when combined with Methadone.
Methazolamide	Methazolamide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Methimazole	The metabolism of Ruxolitinib can be decreased when combined with Methimazole.
Methotrexate	The risk or severity of adverse effects can be increased when Methotrexate is combined with Ruxolitinib.
Methoxsalen	Methoxsalen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Methoxy pol	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ruxolitinib.
Methoxyflurane	The metabolism of Ruxolitinib can be decreased when combined with Methoxyflurane.
Methsuximide	Ruxolitinib may increase the bradycardic activities of Methsuximide.
Methyldopa	Ruxolitinib may increase the bradycardic activities of Methyldopa.
Methylene blue	The metabolism of Ruxolitinib can be decreased when combined with Methylene blue.
Methylergometrine	The metabolism of Ruxolitinib can be decreased when combined with Methylergometrine.
Methylnaltrexone	Methylnaltrexone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Methylphenobarbital	The metabolism of Ruxolitinib can be increased when combined with Methylphenobarbital.
Methylprednisolone	The metabolism of Ruxolitinib can be increased when combined with Methylprednisolone.
Methylprednisone	The metabolism of Ruxolitinib can be decreased when combined with Methylprednisone.
Methyltestosterone	Methyltestosterone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Methysergide	The metabolism of Ruxolitinib can be decreased when combined with Methysergide.
Meticrane	Meticrane may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Metoclopramide	Metoclopramide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Metolazone	Metolazone may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Metoprolol	Ruxolitinib may increase the bradycardic activities of Metoprolol.
Metreleptin	The metabolism of Ruxolitinib can be increased when combined with Metreleptin.
Metronidazole	The metabolism of Ruxolitinib can be decreased when combined with Metronidazole.
Metyrapone	The metabolism of Ruxolitinib can be increased when combined with Metyrapone.
Miconazole	The metabolism of Ruxolitinib can be decreased when combined with Miconazole.
Midazolam	The metabolism of Ruxolitinib can be decreased when combined with Midazolam.
Midodrine	Ruxolitinib may increase the bradycardic activities of Midodrine.
Midostaurin	The metabolism of Ruxolitinib can be decreased when combined with Midostaurin.
Mifepristone	The metabolism of Ruxolitinib can be increased when combined with Mifepristone.
Migalastat	Migalastat may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Milnacipran	The metabolism of Ruxolitinib can be decreased when combined with Milnacipran.
Milrinone	Milrinone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Miocamycin	The metabolism of Ruxolitinib can be decreased when combined with Miocamycin.
Mirabegron	Ruxolitinib may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Mirtazapine	The metabolism of Ruxolitinib can be decreased when combined with Mirtazapine.
Mitapivat	The metabolism of Ruxolitinib can be increased when combined with Mitapivat.
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Ruxolitinib.
Mitotane	The metabolism of Ruxolitinib can be increased when combined with Mitotane.
Mitoxantrone	The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ruxolitinib.
Mobocertinib	The serum concentration of Ruxolitinib can be decreased when it is combined with Mobocertinib.
Modafinil	The metabolism of Ruxolitinib can be increased when combined with Modafinil.
Mo COVID-19	The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Ruxolitinib.

Modified vaccinia ankara	The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Ruxolitinib.
Mometasone furoate	The metabolism of Ruxolitinib can be increased when combined with Mometasone furoate.
Monomethyl fum	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Monomethyl fumarate.
Montelukast	The metabolism of Ruxolitinib can be decreased when combined with Montelukast.
Mosunetuzumab	The metabolism of Ruxolitinib can be decreased when combined with Mosunetuzumab.
Moxisylyte	Ruxolitinib may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
Mumps virus	The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Ruxolitinib.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Ruxolitinib.
Muzolimine	Muzolimine may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Mycophenolate l	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ruxolitinib.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ruxolitinib.
N-acetyltyrosine	Ruxolitinib may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Nabilone	The metabolism of Ruxolitinib can be decreased when combined with Nabilone.
Nabumetone	Nabumetone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Nadolol	Ruxolitinib may increase the bradycardic activities of Nadolol.
Nadroparin	The risk or severity of bleeding can be increased when Nadroparin is combined with Ruxolitinib.
Nafcillin	The metabolism of Ruxolitinib can be increased when combined with Nafcillin.
Naldemedine	Ruxolitinib may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Nalmefene	Nalmefene may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Naloxone	Naloxone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Naproxen	Naproxen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Natalizumab	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Natalizumab.
Nateglinide	Nateglinide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Nebivolol	Ruxolitinib may increase the bradycardic activities of Nebivolol.
Nedaplatin	Ruxolitinib may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
Nedocromil	Nedocromil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Nefazodone	The metabolism of Ruxolitinib can be decreased when combined with Nefazodone.
Nelarabine	The risk or severity of adverse effects can be increased when Nelarabine is combined with Ruxolitinib.
Nelfinavir	The metabolism of Ruxolitinib can be decreased when combined with Nelfinavir.
Neomycin	Ruxolitinib may decrease the excretion rate of Neomycin which could result in a higher serum level.
Netilmicin	Ruxolitinib may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Netupitant	The metabolism of Ruxolitinib can be decreased when combined with Netupitant.
Nevirapine	The metabolism of Ruxolitinib can be decreased when combined with Nevirapine.
Niacin	The metabolism of Ruxolitinib can be decreased when combined with Niacin.
Nicardipine	Ruxolitinib may increase the bradycardic activities of Nicardipine.
Niclosamide	The metabolism of Ruxolitinib can be decreased when combined with Niclosamide.
Nicorandil	Ruxolitinib may decrease the excretion rate of Nicorandil which could result in a higher serum level.
Nifedipine	Ruxolitinib may increase the bradycardic activities of Nifedipine.
Nilotinib	The metabolism of Ruxolitinib can be decreased when combined with Nilotinib.
Nilutamide	The metabolism of Ruxolitinib can be decreased when combined with Nilutamide.
Nilvadipine	Ruxolitinib may increase the bradycardic activities of Nilvadipine.
Nimesulide	Ruxolitinib may increase the bradycardic activities of Nimesulide.
Nimodipine	Ruxolitinib may increase the bradycardic activities of Nimodipine.
Nintedanib	The metabolism of Ruxolitinib can be decreased when combined with Nintedanib.
Nisoldipine	Ruxolitinib may increase the bradycardic activities of Nisoldipine.
Nitrendipine	Ruxolitinib may increase the bradycardic activities of Nitrendipine.
Nitric Oxide	Nitric Oxide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Nitrofurantoin	Nitrofurantoin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Nitroprusside	Nitroprusside may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Norethisterone	The metabolism of Ruxolitinib can be decreased when combined with Norethisterone.
Norgestimate	The metabolism of Ruxolitinib can be increased when combined with Norgestimate.
Noscapine	The metabolism of Ruxolitinib can be decreased when combined with Noscapine.
Nuvaxovid	The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Ruxolitinib.
Nylidrin	Ruxolitinib may increase the bradycardic activities of Nylidrin.
Obinutuzumab	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Obinutuzumab.
Ocrelizumab	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ocrelizumab.
Octinoxate	Ruxolitinib may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Octreotide	The serum concentration of Ruxolitinib can be increased when it is combined with Octreotide.
Ofatumumab	The risk or severity of adverse effects can be increased when Ofatumumab is combined with Ruxolitinib.
Olanzapine	The metabolism of Ruxolitinib can be decreased when combined with Olanzapine.
Olaparib	The metabolism of Ruxolitinib can be decreased when combined with Olaparib.
Olodaterol	The metabolism of Olodaterol can be decreased when combined with Ruxolitinib.
Olsalazine	Olsalazine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Omeprazole	The metabolism of Ruxolitinib can be decreased when combined with Omeprazole.
Ondansetron	The metabolism of Ruxolitinib can be decreased when combined with Ondansetron.
Opium	Ruxolitinib may decrease the excretion rate of Opium which could result in a higher serum level.
Oritavancin	The metabolism of Ruxolitinib can be increased when combined with Oritavancin.
Orphenadrine	The metabolism of Ruxolitinib can be decreased when combined with Orphenadrine.
Oseltamivir	Oseltamivir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Osilodrostat	The metabolism of Ruxolitinib can be decreased when combined with Osilodrostat.
Osimertinib	The metabolism of Ruxolitinib can be decreased when combined with Osimertinib.
Ospemifene	The metabolism of Ruxolitinib can be decreased when combined with Ospemifene.
Oxacillin	Oxacillin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Oxaliplatin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ruxolitinib.
Oxandrolone	The metabolism of Ruxolitinib can be decreased when combined with Oxandrolone.
Oxaprozin	Oxaprozin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Oxazepam	Oxazepam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Oxcarbazepine	The metabolism of Ruxolitinib can be increased when combined with Oxcarbazepine.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Oxetacaine.
Oxprenolol	Ruxolitinib may increase the bradycardic activities of Oxprenolol.
Oxybenzone	Oxybenzone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Oxybuprocaine.
Oxybutynin	The metabolism of Ruxolitinib can be decreased when combined with Oxybutynin.
Oxyphenbutazone	Oxyphenbutazone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Oxyquinoline	Ruxolitinib may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
Ozanimod	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ozanimod.
Paclitaxel	The metabolism of Ruxolitinib can be increased when combined with Paclitaxel.
Pacritinib	The serum concentration of Ruxolitinib can be increased when it is combined with Pacritinib.
Palbociclib	The metabolism of Ruxolitinib can be decreased when combined with Palbociclib.
Palifermin	The therapeutic efficacy of Palifermin can be decreased when used in combination with Ruxolitinib.
Paliperidone	Paliperidone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Palonosetron	Palonosetron may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Pamidronic acid	Pamidronic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Panobinostat	The risk or severity of adverse effects can be increased when Panobinostat is combined with Ruxolitinib.
Pantoprazole	Pantoprazole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Paramethadione	The metabolism of Ruxolitinib can be decreased when combined with Paramethadione.
Parathyroid hormone	The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Ruxolitinib.
Parecoxib	Parecoxib may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Parnaparin	The risk or severity of bleeding can be increased when Parnaparin is combined with Ruxolitinib.
Paromomycin	Paromomycin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.

Paroxetine	The metabolism of Ruxolitinib can be decreased when combined with Paroxetine.
Pasireotide	Ruxolitinib may increase the bradycardic activities of Pasireotide.
Patent Blue	Ruxolitinib may decrease the excretion rate of Patent Blue which could result in a higher serum level.
Pazopanib	The metabolism of Ruxolitinib can be decreased when combined with Pazopanib.
Pegaptanib	Pegaptanib may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ruxolitinib.
Pegcetacoplan	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Pegcetacoplan.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Ruxolitinib.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ruxolitinib.
Peginterferon alfa-2b	The metabolism of Ruxolitinib can be increased when combined with Peginterferon alfa-2b.
Peginterferon beta-1a	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Peginterferon beta-1a.
Pemetrexed	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Ruxolitinib.
Penbutolol	Ruxolitinib may increase the bradycardic activities of Penbutolol.
Penicillamine	The risk or severity of adverse effects can be increased when Penicillamine is combined with Ruxolitinib.
Pentaerythritol tetranitrate	Pentaerythritol tetranitrate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Pentamidine	Pentamidine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Pentastarch	Ruxolitinib may decrease the excretion rate of Pentastarch which could result in a higher serum level.
Pentetic acid	Ruxolitinib may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
Pentobarbital	The metabolism of Ruxolitinib can be increased when combined with Pentobarbital.
Pentosan polysulfate	The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Ruxolitinib.
Pentostatin	The risk or severity of adverse effects can be increased when Pentostatin is combined with Ruxolitinib.
Pentoxifylline	The risk or severity of bleeding can be increased when Pentoxifylline is combined with Ruxolitinib.
Perampanel	The metabolism of Ruxolitinib can be increased when combined with Perampanel.
Perhexiline	Ruxolitinib may increase the bradycardic activities of Perhexiline.
Perindopril	Perindopril may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Permethrin	Permethrin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Pertussis vaccine	The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Ruxolitinib.
Phenazopyridine	Phenazopyridine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Phenelzine	Phenelzine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Phenindione	The risk or severity of bleeding can be increased when Phenindione is combined with Ruxolitinib.
Phenobarbital	The metabolism of Ruxolitinib can be increased when combined with Phenobarbital.
Phenol	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Phenol.
Phenprocoumon	The risk or severity of bleeding can be increased when Phenprocoumon is combined with Ruxolitinib.
Phentolamine	Phentolamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ruxolitinib.
Phenylbutazone	The metabolism of Ruxolitinib can be increased when combined with Phenylbutazone.
Phenytoin	The metabolism of Ruxolitinib can be increased when combined with Phenytoin.
Pholcodine	Ruxolitinib may decrease the excretion rate of Pholcodine which could result in a higher serum level.
Phosphoric acid	Ruxolitinib may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Phylloquinone	Phylloquinone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Picosulfuric acid	Ruxolitinib may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
Pimavanserin	The metabolism of Ruxolitinib can be decreased when combined with Pimavanserin.
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ruxolitinib.
Pimozide	The metabolism of Ruxolitinib can be decreased when combined with Pimozide.
Pinaverium	Ruxolitinib may increase the bradycardic activities of Pinaverium.
Pindolol	Ruxolitinib may increase the bradycardic activities of Pindolol.
Piperacillin	Piperacillin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Piperaquine	The metabolism of Ruxolitinib can be decreased when combined with Piperaquine.
Piracetam	Ruxolitinib may decrease the excretion rate of Piracetam which could result in a higher serum level.
Piretanide	Piretanide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Pirfenidone	The risk or severity of adverse effects can be increased when Pirfenidone is combined with Ruxolitinib.
Piroxicam	Piroxicam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Pitavastatin	The metabolism of Ruxolitinib can be decreased when combined with Pitavastatin.
Pitolisant	The serum concentration of Ruxolitinib can be decreased when it is combined with Pitolisant.
Plazomicin	Ruxolitinib may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Plerixafor	Plerixafor may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Polythiazide	Polythiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Pomalidomide	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Pomalidomide.
Ponatinib	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ponatinib.
Ponesimod	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ponesimod.
Poractant alfa	Ruxolitinib may increase the bradycardic activities of Poractant alfa.
Posaconazole	The metabolism of Ruxolitinib can be decreased when combined with Posaconazole.
Potassium	Potassium may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Potassium acetate	Ruxolitinib may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Potassium bicarb	Ruxolitinib may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
Potassium cation	Potassium cation may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Potassium chloride	Potassium chloride may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Potassium citrate	Potassium citrate may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Potassium Iodide	The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Ruxolitinib.
Potassium nitrate	Ruxolitinib may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Potassium perc	The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Ruxolitinib.
Potassium sulfate	Ruxolitinib may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
Practolol	Ruxolitinib may increase the bradycardic activities of Practolol.
Pralatrexate	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ruxolitinib.
Pralidoxime	Pralidoxime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Pralsetinib	The metabolism of Ruxolitinib can be increased when combined with Pralsetinib.
Pramipexole	Pramipexole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Pramocaine.
Prasugrel	The risk or severity of bleeding can be increased when Prasugrel is combined with Ruxolitinib.
Prednisolone	The metabolism of Ruxolitinib can be increased when combined with Prednisolone.
Prednisolone ace	The metabolism of Ruxolitinib can be increased when combined with Prednisolone acetate.
Prednisolone phosphate	The metabolism of Ruxolitinib can be increased when combined with Prednisolone phosphate.
Prednisone	The risk or severity of adverse effects can be increased when Prednisone is combined with Ruxolitinib.
Prednisone acetate	The metabolism of Ruxolitinib can be increased when combined with Prednisone acetate.
Pregabalin	Ruxolitinib may increase the bradycardic activities of Pregabalin.
Prenylamine	Ruxolitinib may increase the bradycardic activities of Prenylamine.
Pretomanid	The metabolism of Ruxolitinib can be decreased when combined with Pretomanid.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Prilocaine.
Primaquine	The metabolism of Ruxolitinib can be decreased when combined with Primaquine.
Primidone	The metabolism of Ruxolitinib can be increased when combined with Primidone.
Probenecid	The metabolism of Ruxolitinib can be increased when combined with Probenecid.
Procainamide	Ruxolitinib may decrease the excretion rate of Procainamide which could result in a higher serum level.
Procaine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Procaine.
Procaine benzylpenicillin	Ruxolitinib may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Procarbazine	The risk or severity of adverse effects can be increased when Procarbazine is combined with Ruxolitinib.
Progesterone	The metabolism of Ruxolitinib can be decreased when combined with Progesterone.
Proguanil	The metabolism of Ruxolitinib can be decreased when combined with Proguanil.
Promazine	The metabolism of Ruxolitinib can be decreased when combined with Promazine.
Promethazine	The metabolism of Ruxolitinib can be decreased when combined with Promethazine.
Propafenone	Ruxolitinib may increase the bradycardic activities of Propafenone.

Propantheline	Propantheline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Proparacaine.
Propiverine	Ruxolitinib may decrease the excretion rate of Propiverine which could result in a higher serum level.
Propofol	The metabolism of Ruxolitinib can be decreased when combined with Propofol.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Propoxycaine.
Propranolol	Ruxolitinib may increase the bradycardic activities of Propranolol.
Propylthiouracil	The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Ruxolitinib.
Protein C	The risk or severity of bleeding can be increased when Protein C is combined with Ruxolitinib.
Protein S human	The risk or severity of bleeding can be increased when Protein S human is combined with Ruxolitinib.
Protirelin	The therapeutic efficacy of Protirelin can be decreased when used in combination with Ruxolitinib.
Prucalopride	Prucalopride may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Pyrantel	Ruxolitinib may decrease the excretion rate of Pyrantel which could result in a higher serum level.
Pyrazinamide	Pyrazinamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Pyridoxine	Pyridoxine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Pyrithione	Pyrithione may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Quazepam	The metabolism of Ruxolitinib can be decreased when combined with Quazepam.
Quetiapine	Quetiapine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Quinethazone	Quinethazone may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Quinidine	The metabolism of Ruxolitinib can be decreased when combined with Quinidine.
Quinine	The metabolism of Ruxolitinib can be increased when combined with Quinine.
Quinupristin	The metabolism of Ruxolitinib can be decreased when combined with Quinupristin.
Rabeprazole	Rabeprazole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Rimmune globul	The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Ruxolitinib.
Rabie antigen, A	The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ruxolitinib.
Rabie antigen, B	The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Ruxolitinib.
Raloxifene	The metabolism of Ruxolitinib can be decreased when combined with Raloxifene.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Ruxolitinib.
Ramelteon	Ramelteon may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ranitidine	Ranitidine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ranolazine	The metabolism of Ruxolitinib can be decreased when combined with Ranolazine.
Rasagiline	Rasagiline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ravulizumab	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ravulizumab.
Regorafenib	Ruxolitinib may increase the bradycardic activities of Regorafenib.
Remdesivir	The metabolism of Ruxolitinib can be decreased when combined with Remdesivir.
Remifentanil	Ruxolitinib may increase the bradycardic activities of Remifentanil.
Reserpine	Reserpine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Resorcinol	Ruxolitinib may decrease the excretion rate of Resorcinol which could result in a higher serum level.
Reteplase	The risk or severity of bleeding can be increased when Reteplase is combined with Ruxolitinib.
Reviparin	The risk or severity of bleeding can be increased when Reviparin is combined with Ruxolitinib.
Ribavirin	Ribavirin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ribociclib	The metabolism of Ruxolitinib can be decreased when combined with Ribociclib.
Ribostamycin	Ruxolitinib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.
Rifabutin	The metabolism of Ruxolitinib can be increased when combined with Rifabutin.
Rifampicin	The metabolism of Ruxolitinib can be increased when combined with Rifampicin.
Rifamycin	The metabolism of Ruxolitinib can be increased when combined with Rifamycin.
Rifapentine	The metabolism of Ruxolitinib can be increased when combined with Rifapentine.
Rilonacept	The metabolism of Ruxolitinib can be increased when combined with Rilonacept.
Rilpivirine	The metabolism of Ruxolitinib can be decreased when combined with Rilpivirine.
Rimexolone	The metabolism of Ruxolitinib can be increased when combined with Rimexolone.
Risankizumab	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Risankizumab.
Ritonavir	The metabolism of Ruxolitinib can be decreased when combined with Ritonavir.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Ruxolitinib.
Rivaroxaban	Rivaroxaban may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Rivastigmine	Ruxolitinib may increase the bradycardic activities of Rivastigmine.
Rizatriptan	Rizatriptan may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Rofecoxib	The metabolism of Ruxolitinib can be increased when combined with Rofecoxib.
Roflumilast	Roflumilast may increase the immunosuppressive activities of Ruxolitinib.
Ropeginterferon	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ropeginterferon alfa-2b.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Ropivacaine.
Rosiglitazone	Rosiglitazone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Rosuvastatin	The metabolism of Ruxolitinib can be decreased when combined with Rosuvastatin.
Rotavirus vaccine	The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Ruxolitinib.
Roxithromycin	The metabolism of Ruxolitinib can be decreased when combined with Roxithromycin.
Rubella virus va	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Ruxolitinib.
Rucaparib	The metabolism of Ruxolitinib can be decreased when combined with Rucaparib.
Rufinamide	The metabolism of Ruxolitinib can be increased when combined with Rufinamide.
Rupatadine	The metabolism of Rupatadine can be decreased when combined with Ruxolitinib.
Sacubitril	Ruxolitinib may decrease the excretion rate of Sacubitril which could result in a higher serum level.
Salbutamol	Salbutamol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Salicylamide	Salicylamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Salicylic acid	Salicylic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Salmon calcitonin	The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Ruxolitinib.
Salsalate	Salsalate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Saquinavir	The metabolism of Ruxolitinib can be decreased when combined with Saquinavir.
Sarilumab	The metabolism of Ruxolitinib can be increased when combined with Sarilumab.
Satralizumab	The serum concentration of Ruxolitinib can be decreased when it is combined with Satralizumab.
Saxagliptin	Saxagliptin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Secobarbital	The metabolism of Ruxolitinib can be increased when combined with Secobarbital.
Secukinumab	The metabolism of Ruxolitinib can be increased when combined with Secukinumab.
Selegiline	The metabolism of Ruxolitinib can be decreased when combined with Selegiline.
Selenious acid	Ruxolitinib may decrease the excretion rate of Selenious acid which could result in a higher serum level.
Selenium	Ruxolitinib may decrease the excretion rate of Selenium which could result in a higher serum level.
Selumetinib	The metabolism of Selumetinib can be decreased when combined with Ruxolitinib.
Sertraline	The metabolism of Ruxolitinib can be decreased when combined with Sertraline.
Sibutramine	Sibutramine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Sildenafil	The metabolism of Ruxolitinib can be decreased when combined with Sildenafil.
Siltuximab	The metabolism of Ruxolitinib can be increased when combined with Siltuximab.
Simeprevir	The metabolism of Ruxolitinib can be decreased when combined with Simeprevir.
Simvastatin	The metabolism of Ruxolitinib can be decreased when combined with Simvastatin.
Siponimod	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Siponimod.
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ruxolitinib.
Sirolimus	The risk or severity of adverse effects can be increased when Sirolimus is combined with Ruxolitinib.
Sitagliptin	Sitagliptin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Sitaxentan	The metabolism of Ruxolitinib can be decreased when combined with Sitaxentan.
Smallpox (Vaccinia)	The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Ruxolitinib.
Sodium acetate	Ruxolitinib may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
Sodium aurothiomalate	Ruxolitinib may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
Sodium citrate	The risk or severity of bleeding can be increased when Sodium citrate is combined with Ruxolitinib.
Sodium fluoride	Ruxolitinib may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
Sodium sulfate	Ruxolitinib may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.

Sofosbuvir	Ruxolitinib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Solriamfetol	Ruxolitinib may decrease the excretion rate of Solriamfetol which could result in a higher serum level.
Somatostatin	The metabolism of Ruxolitinib can be decreased when combined with Somatostatin.
Somatrogon	The metabolism of Ruxolitinib can be increased when combined with Somatrogon.
Sorafenib	The risk or severity of adverse effects can be increased when Sorafenib is combined with Ruxolitinib.
Sorbitol	Sorbitol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Sotalol	Ruxolitinib may increase the bradycardic activities of Sotalol.
Sotorasib	The serum concentration of Ruxolitinib can be decreased when it is combined with Sotorasib.
Spesolimab	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Spesolimab.
Spironolactone	Spironolactone may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
St. John’s Wort	The metabolism of Ruxolitinib can be increased when combined with St. John’s Wort.
Stiripentol	The metabolism of Ruxolitinib can be decreased when combined with Stiripentol.
Streptokinase	The risk or severity of bleeding can be increased when Streptokinase is combined with Ruxolitinib.
Streptomycin	Ruxolitinib may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Ruxolitinib.
Strontium chloride	Ruxolitinib may decrease the excretion rate of Strontium chloride which could result in a higher serum level.
Sucralfate	Sucralfate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Sufentanil	Ruxolitinib may increase the bradycardic activities of Sufentanil.
Sulbactam	Ruxolitinib may decrease the excretion rate of Sulbactam which could result in a higher serum level.
Sulfadiazine	The metabolism of Ruxolitinib can be decreased when combined with Sulfadiazine.
Sulfamethizole	The metabolism of Ruxolitinib can be decreased when combined with Sulfamethizole.
Sulfamethoxazole	The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ruxolitinib.
Sulfaphenazole	The metabolism of Ruxolitinib can be decreased when combined with Sulfaphenazole.
Sulfapyridine	The metabolism of Ruxolitinib can be decreased when combined with Sulfapyridine.
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ruxolitinib.
Sulfinpyrazone	The metabolism of Ruxolitinib can be increased when combined with Sulfinpyrazone.
Sulfisoxazole	The metabolism of Ruxolitinib can be decreased when combined with Sulfisoxazole.
Sulindac	Sulindac may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Sulodexide	The risk or severity of bleeding can be increased when Sulodexide is combined with Ruxolitinib.
Sumatriptan	Sumatriptan may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Sunitinib	The risk or severity of adverse effects can be increased when Sunitinib is combined with Ruxolitinib.
Suvorexant	The metabolism of Ruxolitinib can be decreased when combined with Suvorexant.
Syn Estrogens, A	Ruxolitinib may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
Syn  Estrogens, B	Ruxolitinib may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
Tacrolimus	Tacrolimus may increase the immunosuppressive activities of Ruxolitinib.
Tadalafil	Tadalafil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tamoxifen	The metabolism of Ruxolitinib can be increased when combined with Tamoxifen.
Tamsulosin	Tamsulosin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tasimelteon	The metabolism of Ruxolitinib can be decreased when combined with Tasimelteon.
Tazemetostat	The metabolism of Ruxolitinib can be decreased when combined with Tazemetostat.
Technetium T	Ruxolitinib may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
Technetium	Ruxolitinib may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.
Technetium Tc-99	Ruxolitinib may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.
Technetium Tc-99m p	Ruxolitinib may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
Tecovirimat	The metabolism of Ruxolitinib can be increased when combined with Tecovirimat.
Tedizolid phosphate	The risk or severity of myelosuppression can be increased when Ruxolitinib is combined with Tedizolid phosphate.
Teduglutide	Ruxolitinib may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Tegafur	Ruxolitinib may decrease the excretion rate of Tegafur which could result in a higher serum level.
Telaprevir	The metabolism of Ruxolitinib can be decreased when combined with Telaprevir.
Telavancin	Telavancin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Telithromycin	The metabolism of Ruxolitinib can be decreased when combined with Telithromycin.
Telotristat ethyl	The serum concentration of Ruxolitinib can be decreased when it is combined with Telotristat ethyl.
Temazepam	Temazepam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Temozolomide	The risk or severity of adverse effects can be increased when Temozolomide is combined with Ruxolitinib.
Temsirolimus	The risk or severity of adverse effects can be increased when Temsirolimus is combined with Ruxolitinib.
Tenecteplase	The risk or severity of bleeding can be increased when Tenecteplase is combined with Ruxolitinib.
Teniposide	The metabolism of Ruxolitinib can be decreased when combined with Teniposide.
Tenofovir alafenamide	The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ruxolitinib.
Tenofovir disoproxil	Tenofovir disoproxil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tenoxicam	Tenoxicam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tepotinib	The metabolism of Ruxolitinib can be decreased when combined with Tepotinib.
Teprotumumab	The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ruxolitinib.
Terbinafine	The metabolism of Ruxolitinib can be increased when combined with Terbinafine.
Terbutaline	Terbutaline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Terfenadine	The metabolism of Ruxolitinib can be decreased when combined with Terfenadine.
Teriflunomide	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Teriflunomide.
Teriparatide	The therapeutic efficacy of Teriparatide can be decreased when used in combination with Ruxolitinib.
Testolactone	Testolactone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Testosterone	The metabolism of Ruxolitinib can be increased when combined with Testosterone.
Testosterone cypionate	Ruxolitinib may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
Testosterone ena	Ruxolitinib may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
Testosterone propi	Testosterone propionate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Testosterone undeca	Ruxolitinib may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Tetracaine.
Tetracycline	The metabolism of Ruxolitinib can be decreased when combined with Tetracycline.
Tetradecyl hydrogen	Ruxolitinib may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
Thalidomide	The risk or severity of adverse effects can be increased when Thalidomide is combined with Ruxolitinib.
Thiabendazole	Thiabendazole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Thiamylal	The metabolism of Ruxolitinib can be increased when combined with Thiamylal.
Thiethylperazine	Thiethylperazine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Thiotepa	The risk or severity of adverse effects can be increased when Thiotepa is combined with Ruxolitinib.
Thyroid, porcine	The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Ruxolitinib.
Thyrotropin alfa	The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Ruxolitinib.
Tiaprofenic acid	Tiaprofenic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ticagrelor	The metabolism of Ruxolitinib can be decreased when combined with Ticagrelor.
Tick-borne ence	The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Ruxolitinib.
Ticlopidine	The metabolism of Ruxolitinib can be decreased when combined with Ticlopidine.
Tiludronic acid	Tiludronic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Timolol	Ruxolitinib may increase the bradycardic activities of Timolol.
Tinidazole	Tinidazole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tinzaparin	The risk or severity of bleeding can be increased when Tinzaparin is combined with Ruxolitinib.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Ruxolitinib.
Tiopronin	Tiopronin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tiotropium	Tiotropium may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tipranavir	The metabolism of Ruxolitinib can be decreased when combined with Tipranavir.
Tirofiban	The risk or severity of bleeding can be increased when Tirofiban is combined with Ruxolitinib.
Tixocortol	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Tixocortol.
Tizanidine	Ruxolitinib may increase the bradycardic activities of Tizanidine.
Tobramycin	Ruxolitinib may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tocilizumab	The metabolism of Ruxolitinib can be increased when combined with Tocilizumab.

Tocopherol	Ruxolitinib may decrease the excretion rate of Tocopherol which could result in a higher serum level.
Tofacitinib	Ruxolitinib may increase the immunosuppressive activities of Tofacitinib.
Tolazamide	Tolazamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tolbutamide	Tolbutamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tolcapone	Tolcapone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tolfenamic acid	Ruxolitinib may increase the bradycardic activities of Tolfenamic acid.
Tolmetin	Tolmetin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tolterodine	Tolterodine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tolvaptan	Tolvaptan may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Topiramate	The metabolism of Ruxolitinib can be increased when combined with Topiramate.
Topotecan	The risk or severity of adverse effects can be increased when Topotecan is combined with Ruxolitinib.
Torasemide	The metabolism of Ruxolitinib can be decreased when combined with Torasemide.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Ruxolitinib.
Trabectedin	The risk or severity of adverse effects can be increased when Trabectedin is combined with Ruxolitinib.
Tramadol	Tramadol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Trametinib	Ruxolitinib may decrease the excretion rate of Trametinib which could result in a higher serum level.
Tranylcypromine	The metabolism of Ruxolitinib can be decreased when combined with Tranylcypromine.
Trastuzumab	Trastuzumab may increase the neutropenic activities of Ruxolitinib.
Trastuzumab	The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Ruxolitinib.
Treprostinil	The metabolism of Ruxolitinib can be decreased when combined with Treprostinil.
Tretinoin	The risk or severity of adverse effects can be increased when Tretinoin is combined with Ruxolitinib.
Triamcinolone	The metabolism of Ruxolitinib can be increased when combined with Triamcinolone.
Triamterene	Triamterene may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Triazolam	Triazolam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Trichlormethiazide	Trichlormethiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Triclabendazole	The metabolism of Ruxolitinib can be decreased when combined with Triclabendazole.
Triethylenetetramine	Triethylenetetramine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Trifluridine	The risk or severity of adverse effects can be increased when Trifluridine is combined with Ruxolitinib.
Triflusal	The risk or severity of bleeding can be increased when Triflusal is combined with Ruxolitinib.
Trilostane	The risk or severity of adverse effects can be increased when Trilostane is combined with Ruxolitinib.
Trimebutine	Ruxolitinib may increase the bradycardic activities of Trimebutine.
Trimethadione	Ruxolitinib may increase the bradycardic activities of Trimethadione.
Trimethoprim	Trimethoprim may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Trimetrexate	Trimetrexate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Trimipramine	The metabolism of Ruxolitinib can be decreased when combined with Trimipramine.
Troglitazone	The metabolism of Ruxolitinib can be increased when combined with Troglitazone.
Troleandomycin	The metabolism of Ruxolitinib can be decreased when combined with Troleandomycin.
Tropisetron	Ruxolitinib may decrease the excretion rate of Tropisetron which could result in a higher serum level.
Tucatinib	The metabolism of Tucatinib can be decreased when combined with Ruxolitinib.
Typhoid vaccine	The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Ruxolitinib.
Typhoid Vaccine Live	The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Ruxolitinib.
Typhoid Vi polys	The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Ruxolitinib.
Ublituximab	The risk or severity of infection can be increased when Ublituximab is combined with Ruxolitinib.
Upadacitinib	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Upadacitinib.
Urokinase	The risk or severity of bleeding can be increased when Urokinase is combined with Ruxolitinib.
Vaborbactam	Ruxolitinib may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
Valaciclovir	Valaciclovir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Valbenazine	Ruxolitinib may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Valdecoxib	The metabolism of Ruxolitinib can be decreased when combined with Valdecoxib.
Valganciclovir	Valganciclovir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Valproic acid	The metabolism of Ruxolitinib can be decreased when combined with Valproic acid.
Valsartan	The metabolism of Ruxolitinib can be decreased when combined with Valsartan.
Vancomycin	Ruxolitinib may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Varenicline	Varenicline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Varicella zoster va	The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Ruxolitinib.
Varicella zoster	The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Ruxolitinib.
Vedolizumab	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Vedolizumab.
Vemurafenib	The metabolism of Ruxolitinib can be increased when combined with Vemurafenib.
Venetoclax	The metabolism of Ruxolitinib can be decreased when combined with Venetoclax.
Venlafaxine	Venlafaxine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Verapamil	Ruxolitinib may increase the bradycardic activities of Verapamil.
Vibrio cholerae	The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Ruxolitinib.
Vilanterol	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Vilanterol.
Viloxazine	The metabolism of Ruxolitinib can be decreased when combined with Viloxazine.
Vinblastine	The metabolism of Ruxolitinib can be increased when combined with Vinblastine.
Vincristine	The risk or severity of adverse effects can be increased when Vincristine is combined with Ruxolitinib.
Vindesine	The risk or severity of adverse effects can be increased when Vindesine is combined with Ruxolitinib.
Vinorelbine	The risk or severity of adverse effects can be increased when Vinorelbine is combined with Ruxolitinib.
Vismodegib	The metabolism of Ruxolitinib can be decreased when combined with Vismodegib.
Vitamin E	The metabolism of Ruxolitinib can be increased when combined with Vitamin E.
Voclosporin	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Voclosporin.
Vorapaxar	The metabolism of Ruxolitinib can be decreased when combined with Vorapaxar.
Voriconazole	The metabolism of Ruxolitinib can be decreased when combined with Voriconazole.
Vorinostat	The risk or severity of adverse effects can be increased when Vorinostat is combined with Ruxolitinib.
Vortioxetine	Ruxolitinib may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
Voxelotor	The serum concentration of Ruxolitinib can be increased when it is combined with Voxelotor.
Warfarin	The metabolism of Ruxolitinib can be increased when combined with Warfarin.
Ximelagatran	The risk or severity of bleeding can be increased when Ximelagatran is combined with Ruxolitinib.
Yellow fever vaccine	The risk or severity of infection can be increased when Yellow fever vaccine is combined with Ruxolitinib.
Zafirlukast	The metabolism of Ruxolitinib can be decreased when combined with Zafirlukast.
Zaleplon	Zaleplon may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Zanamivir	Zanamivir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Zidovudine	The risk or severity of adverse effects can be increased when Zidovudine is combined with Ruxolitinib.
Zileuton	The metabolism of Ruxolitinib can be decreased when combined with Zileuton.
Zimelidine	The metabolism of Ruxolitinib can be decreased when combined with Zimelidine.
Ziprasidone	The metabolism of Ruxolitinib can be decreased when combined with Ziprasidone.
Zolpidem	The metabolism of Ruxolitinib can be decreased when combined with Zolpidem.
Zonisamide	Ruxolitinib may increase the bradycardic activities of Zonisamide.
Zopiclone	The metabolism of Ruxolitinib can be decreased when combined with Zopiclone.
Zuclopenthixol	The metabolism of Ruxolitinib can be decreased when combined with Zuclopenthixol.

Pregnancy and Lactation

AU TGA pregnancy category: C
US FDA pregnancy category: N

Pregnancy

When pregnant rats and rabbits were administered ruxolitinib during the period of organogenesis adverse developmental outcomes occurred at doses associated with maternal toxicity (see Data). There are no studies on the use of Jakafi in pregnant women to inform drug-associated risks. The background risk of major birth defects and miscarriage for the indicated populations is unknown. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. The background risk in the U.S. general population of major birth defects is 2% to 4% and miscarriage is 15% to 20% of clinically recognized pregnancies.

Lactation

No information is available on the clinical use of ruxolitinib during breastfeeding. Because ruxolitinib is 97% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during ruxolitinib therapy and for 2 weeks after the last dose.

Why is this medication prescribed?

Ruxolitinib is used to treat myelofibrosis (a cancer of the bone marrow in which the bone marrow is replaced by scar tissue and causes decreased blood cell production). It is also used to treat polycythemia vera (PV; a slow growing cancer of the blood in which the bone marrow makes too many red blood cells) in people who were not able to be treated successfully with hydroxyurea. Ruxolitinib is also used to treat acute graft versus host disease (aGVHD; a complication of hematopoietic stem-cell transplant [HSCT; a procedure that replaces diseased bone marrow with healthy bone marrow] that usually develops within the first months after HSCT) in adults and children 12 years of age and older who were treated unsuccessfully with steroid medications. It is also used to treat chronic GVHD (cGVHD; a complication of HSCT that usually develops at least 3 months after HSCT) in adults and children 12 years of age and older who were treated unsuccessfully with 1 or 2 other treatments. Ruxolitinib is in a class of medications called kinase inhibitors. It works to treat myelofibrosis and PV by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells. It works to treat GVHD by blocking the signals of the cells that cause GVHD.

How should this medicine be used?

Ruxolitinib comes as a tablet to take by mouth. It is usually taken with or without food two times a day. Take ruxolitinib at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take ruxolitinib exactly as directed. Do not take more or less of it, or take it more often than prescribed by your doctor.

If you are being treated for myelofibrosis or PV your doctor may start you on a low dose of ruxolitinib for the first four weeks of treatment, and gradually increase your dose after that time, not more than once every 2 weeks. If you are being treated for acute GVHD your doctor may start you on a low dose of ruxolitinib and may increase your dose after at least 3 days of therapy. If you are being treated for acute or chronic GVHD your doctor may gradually lower your dose of ruxolitinib after at least 6 months of therapy.

Swallow the tablets whole; do not chew or crush them.

If you can not have food by mouth and have a nasogastric (NG) tube, your doctor may tell you to take ruxolitinib through the nasogastric (NG) tube. Your doctor or pharmacist will explain how to prepare ruxolitinib to give through an NG tube.

Your doctor will order blood tests before and during your treatment to see how you are affected by this medication. Your doctor may increase or decrease your dose of ruxolitinib during your treatment, or may tell you to stop taking ruxolitinib for awhile. This depends on how well the medication works for you, your lab test results, and if you experience side effects. Talk to your doctor about how you are feeling during your treatment. Continue to take ruxolitinib even if you feel well. Do not stop taking ruxolitinib without talking to your doctor. If your doctor decides to stop your treatment with ruxolitinib, your doctor may decrease your dose gradually. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

What special precautions should I follow?

Before taking ruxolitinib,

• tell your doctor and pharmacist if you are allergic to ruxolitinib, any other medications, or any of the ingredients in ruxolitinib. Ask your pharmacist for a list of the ingredients.
• tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: antifungal medications including itraconazole (Sporanox), ketoconazole, and voriconazole (Vfend); carbamazepine (Carbatrol, Equetro, Tegretol, others); clarithromycin; efavirenz (Sustiva, in Atripla, Symfi); erythromycin (E.E.S, Eryc, Ery-tab); fluconazole (Diflucan); HIV protease inhibitors including indinavir (Crixivan), nelfinavir (Viracept), ritonavir (Norvir, in Kaletra, Viekira Pak), and saquinavir (Invirase); nefazodone; nevirapine (Viramune); phenytoin (Dilantin, Phenytek); pioglitazone (Actos, in Oseni, Duetact); rifabutin (Mycobutin); rifampin (Rifadin, Rimactane, in Rifamate, Rifater); and telaprevir (Incivik). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with ruxolitinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
• tell your doctor what herbal products you are taking, especially St. John’s wort.
• tell your doctor if you have anemia, an infection, if you are on dialysis, or if you were recently around someone who has tuberculosis (TB, a severe lung infection) or visited or lived where TB is common. Also tell your doctor if you are a current or past smoker; if you have or have ever had TB; high cholesterol or triglycerides; a blood clot, heart attack, stroke, or other heart problems; skin cancer; herpes zoster (shingles); hepatitis B or other liver disease; or kidney disease.
• tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. If you become pregnant while taking ruxolitinib, call your doctor. You should not breast-feed while taking ruxolitinib and for 2 weeks after your final dose.

What special dietary instructions should I follow?

Unless your doctor tells you otherwise, continue your normal diet.

What should I do if I forget a dose?

Skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

Show More